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ABSTRACT
Prostaglandin F2α (PGF2α) has been shown to have detrimental effects on
embryonic development, quality and hatching ability of embryos and pregnancy rates in
cows. However, information about PGF2α receptor (FPr) mRNA and protein in the preattachment bovine embryo is absent in the literature. The first experiment was design to
identify the period of time during in vitro embryo development that is most susceptible to
PGF2α and to determine FPr mRNA and protein in bovine embryos. Prostaglandin F2α
decreased development of embryos to compact morula, but had no effect on development
to blastocyst. In addition, FPr mRNA and protein was confirmed by real time PCR and
Western Blot analysis, respectively, suggesting that PGF2α is having a direct negative
effect on in vitro development of bovine embryos by activating its receptor.
Discovery of FPr in bovine embryos allowed for development of new therapeutic
strategies aimed at improving reproduction in bovines. Therefore, in a second
experiment, the effects of a selective FPr antagonist, AL-8810, on in vitro development
of bovine embryos was evaluated. The antagonist did not have toxic effects on
development of embryos. Subsequently, efficacy of AL-8810 to prevent PGF2α effects on
pre-compacted embryos was investigated. Results showed that addition of AL-8810 to
the culture medium inhibited PGF2α effects on development to morula stage.
In a third experiment, embryonic development and gene expression of Na+/K+
ATPase α1 and zonula occludens-1 (ZO-1), two important genes participating in
blastocyst formation and hatching, was examined after culture of in vivo-derived
frozen/thawed bovine embryos with AL-8810, PGF, AL-8810+PGF, or Control.
Thereafter, pregnancy rates of embryos recovered with medium containing AL-8810 was
iv

evaluated. Results indicated that AL-8810 inhibited negative effects of PGF2α on
development of embryos; however, no differences in gene expression were observed.
Furthermore, recovery of embryos with medium containing AL-8810 improved
pregnancy rates following transfer to recipient cows. In conclusion, inhibition of PGF2α
binding to its receptors on in vitro- and in vivo-derived bovine embryos increases
embryonic development and pregnancy rates after transfer to recipient animals;
respectively. These findings will likely increase efficiency of in vitro production of
embryos and embryo transfer programs in cattle.
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CHAPTER 1
INTRODUCTION
Reproductive losses associated with the beef industry in the United States are
estimated to cost $500 million dollars annually (Bellows et al., 2002). Early embryonic
death accounts for 75 to 80% of all reproductive losses (Sreenan and Diskin, 1983). The
majority of these losses occur when the embryo enters the uterus (5-8 days after mating
or insemination) and the morula stage embryo is developing into blastocyst (Ayalon,
1978; Maurer and Chenault, 1983; Sreenan and Diskin, 1983; Wiebold, 1988; Dunne et
al., 2000).
Prostaglandins are potent chemical mediators derived from arachidonic acid
metabolism that participate in several physiological processes. Studies have linked
prostaglandins with several pathological conditions such as cancer, inflammation, and
neurodegenerative diseases (Ishihara et al., 2004; Hoozemans and O'Banion, 2005). In
cattle, elevated prostaglandin F2α (PGF2α) concentrations in the uterine lumen has also
been shown to lower reproductive efficiency by decreasing embryonic survival and
development (Harper and Skarnes, 1972; Maurer and Beier, 1976; Breuel et al., 1993;
Schrick et al., 1993; Buford et al., 1996; Hockett et al., 2004; Scenna et al., 2004),
decreasing the ability of bovine embryos to escape from the zona pellucida (hatching;
(Scenna et al., 2004)), and by decreasing pregnancy rates (Lemaster et al., 1999; Sales et
al., 2004; Scenna et al., 2005). Further implications for PGF2α as an embryotoxic agent
was observed when administration of several prostaglandin synthesis inhibitors increased
pregnancy rates after embryo transfer in cows (Elli et al., 2001; McNaughtan et al., 2002;
Pugh et al., 2004; Purcell et al., 2004; Scenna et al., 2005).
1

To date, the mechanisms through which PGF2α reduces embryonic survival and
development in the cow are still unclear. In addition, the presence of prostaglandin PGF2α
receptors (FPr) in pre-attachment bovine embryos has not been documented in the
literature. Therefore, the objectives of this dissertation were 1) to identify the period of
time during in vitro embryo development where the embryo is most susceptible to
detrimental effects of PGF2α, 2) to determine the presence of FPr mRNA and protein in
bovine embryos; 3) to inhibit detrimental effects of PGF2α on embryo development by
addition of a selective FPr antagonist, AL-8810, to the culture medium of embryos
treated with PGF2α; and lastly 4) to improve pregnancy rates after bovine embryo transfer
by transferring embryos treated with AL-8810.
In conclusion, PGF2α is a primary cause of embryonic loss in cattle. Therefore,
understanding the mechanism/s by which PGF2α causes its effects on the embryo will
allow the development of new therapeutic strategies to improve embryo quality,
development and survival. These improvements will result in better production efficiency
(due to an increase in pregnancy rates and subsequent calving rates) and higher monetary
earnings to the cattle industry (due to an increase in cattle sales).
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CHAPTER 2
LITERATURE REVIEW
1. Early embryonic development
Establishment of a viable pregnancy in cattle depends on many complex
processes. Functional gametes must be produced by both sexes, the female must show
estrus, mating must occurr within the functional lifespan of the gametes, and proper
uterine environment and corpus luteum functionality must ensure embryonic and fetal
development.
In the cow, a population of primordial follicles containing an oocyte arrested at
prophase of the first meiotic division (immature oocyte) is established during fetal life
(van Wezel and Rodgers, 1996). During each estrous cycle, two or three follicular waves
occur in which a group of follicles are recruited to initiate growth (Savio et al., 1988;
Ginther et al., 1989; Fortune, 1993). During each follicular wave, only one of these
follicles becomes dominant and continues to grow, while subordinate follicles regress
(Knopf et al., 1989). Upon luteolysis (destruction of the corpus luteum by PGF2α), the
dominant follicle increases in size and produces estradiol 17β to “trigger” a preovulatory
peak of luteinizing hormone (LH) and estrous behavior. Luteinizing hormone causes the
oocyte in the dominant follicle to resume meiosis (progresses to metaphase of the second
meiotic division) and ovulation to take place (Espey, 1994).
After expulsion of the matured oocyte from the ovulatory follicle, the oocyte is
collected by the oviduct. The oviduct is comprised of four distinct regions: infundibulum,
ampulla, ampullary-isthmic junction, and isthmus (Ellington, 1991). The mature oocyte is
3

captured by the infundibulum and transported to the ampullary-isthmus junction where
capacitated sperm bind to the zona pellucida surrounding the oocyte, undergoes acrosome
reaction and penetrates the oocyte’s plasma membrane (Saling, 1991). After fertilization
and organization of the male and female pronuclei, the zygote becomes an embryo that
undergoes a series of synchronized cell divisions (also called cleavage divisions; Figure
1).
The first cleavage division generates a two-cell embryo, in which cells are called
blastomeres. As the early embryo is transported through the isthmus region of the
oviduct, each blastomere undergoes subsequent divisions yielding 4-, 8-, 16- and 32-cell
embryos (Figure 1). The embryo enters the uterine horn on day 5-6 after estrus; at which
time, blastomeres flatten against each other forming a “solid ball” of cells called a morula
(Figure 1). The morula stage embryo begins to form a fluid filled cavity (the blastocoele)
and the embryo is classified as a blastocyst (Watson et al., 1992). Throughout all these
developmental stages, blastomeres become smaller with no net increase in size of the
embryo. Further accumulation of fluid within the blastocoele allows the embryo to
expand (expanded blastocyst) and finally hatch (escape) from the zona pellucida (hatched
blastocyst) on approximately day 9 after estrus (Van Soom et al., 1997).
In cattle, hatching is a critical step for a successful pregnancy because it allows
filamentous development of the embryo and posterior attachment of the embryo to the
uterine endometrium. Similarly, low implantation rates of in vitro-fertilized human
embryos are largely due to impaired development and hatching of blastocyst (Magli et
al., 1998).

4

Polarization
Tight Junctions
Gap Junctions
E-cadherin

E-cadherin activation
Compaction
EGA

Cleavage Divisions

Oocyte 2-cell 4-cell
Day 1 Day 2

8- to 16- cell E. Morula C. Morula Blastocyst
Day 7
Day 6
Day 3 and 4 Day 5

Figure 1. Important events during development of bovine embryos. After fertilization, the
zygote suffers a series of well orchestrated cell divisions (cleavage divisions) leading to
the formation of first a compact morula (C. Morula) and later a blastocyst stage embryo.
Presence of maternally inherited and embryonic E-cadherin allows compaction to occur.
Following compaction, outer cells of the compact morula develop tight junctions,
whereas inner cells develop gap junctions. Outer cells polarize and differentiate in
trophectoderm cells, whereas inner cells remain apolar and differentiate into the inner cell
mass. EGA= embryonic genome activation. Approximate days after insemination are
depicted for every stage of development.
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2. Embryonic genome activation and gene expression in bovine embryos
After fertilization of the oocyte, several important events occur during
development of an early bovine embryo. These include the first cleavage division, the
activation of the embryonic genome, compaction, formation of the blastocoele and cell
differentiation. Embryonic genome activation is considered the most important of these
events due to the fact that it leads the way to further development. Without genome
activation, an early bovine embryo stops development at the 8 to 16-cell stage embryo, a
phenomenon known as “developmental block” (Meirelles et al., 2004). Maternal mRNAs
and proteins, accumulated in the oocyte’s cytoplasm during its growing phase within the
follicle, are able to support early embryonic divisions (Briggs et al., 1951; Fair et al.,
1997). However, further development is achieved only by activation of the embryonic
genome, which allows the embryo to synthesize its own mRNA and proteins. Initiation of
this process differs between species: 1-cell stage in the mouse (Aoki et al., 1997), 4-cell
stage in humans (Braude et al., 1988), and 8- to 16-cell stage in cattle (Camous et al.,
1986), sheep (Crosby et al., 1988), and rabbits (Manes, 1973).
In the mouse, the majority of maternal proteins and mRNA are degraded during
transition from maternal to embryonic genome activation (Latham et al., 1991). In fact,
adenylation and degradation of maternal mRNA are initiated during meiotic maturation
and results in a net loss of 30% of polyadenylated mRNA pools between fully grown
oocytes and ovulated oocytes (Bachvarova et al., 1985). Active turnover of mRNA
continues and the majority of poly-A tail mRNA is degraded by the 2-cell stage embryo
(Piko and Clegg, 1982). At the same time, a major activation of the embryonic genome
occurs (Aoki et al., 1997). About 50% of these newly synthesized transcripts are absent
6

from the maternal population of mRNA (Taylor and Piko, 1987). During maternal to
embryonic genome activation in the mouse, ribosomal RNA and ribosome numbers
decrease only 25% (Piko and Clegg, 1982). Moreover, small nuclear RNAs (snRNAs)
from maternal origin, responsible for processing new transcripts into functional mRNA,
are not degraded during the transition from maternal to embryonic genome activation
(Dean et al., 1989). This suggests that in the mouse, mRNA synthesized during
embryonic genome activation appears to be processed by snRNAs of maternal origin.
In the cow, a gradual decrease in protein concentration is observed from the
oocyte through the 8-cell stage (Frei et al., 1989). Following embryonic genome
activation at the 8-cell stage embryo, a marked increase in total mRNA and proteins
occurs (Camous et al., 1986; Frei et al., 1989). Memili and coworkers (1998) suggested a
minor genome activation between the 1- and the late 4-cell stages and a major genome
activation at the 8-cell stage in bovine embryos. There is a positive correlation between
genome activation and the duration of the cell cycle in bovine embryos (Barnes and
Eyestone, 1990). The total length for the first cell cycle is 28 h, 24 h for the second cell
cycle (without G1 or G2), 14 h for the third cell cycle (without G1), and 24-28 h for the
fourth cell cycle (with both G1 and G2, coinciding with the activation of the embryonic
genome). During embryonic genome activation, several important genes for cell
proliferation, compaction and blastocyst formation are activated. Some of those genes
include expression of growth factors and their receptors (Rappolee et al., 1990), cell
adhesion molecules (Kidder, 1987) and Na+/K+ ATPase enzyme (Watson and Kidder,
1988).
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3. Protein content of bovine oocytes and embryos
A major feature of mammalian embryogenesis is a marked change in the pattern
of protein synthesis as the embryo proceeds through early cleavage divisions. During this
period of time, populations of both maternal RNA and proteins that had been stored in the
oocyte during oogenesis are sufficient to support early embryonic development to the 2
cell stage in mouse (Golbus et al., 1973), 4-8 cell stage in humans (Braude et al., 1988),
8-cell stage rabbits (Manes and Daniel, 1969; Schultz et al., 1973) and 8 to16-cell stage
in sheep and bovine embryos (Crosby et al., 1988; Frei et al., 1989). Due to degradation
of these stored molecules, subsequent development is dependent upon transcriptional
activation of the embryonic genome.
Protein synthesis of bovine oocytes and early stage embryos (up to 16-cell stage)
was first analyzed by Frei et al. (1989) after culturing in vivo-derived embryos in medium
containing radiolabelled methionine. In this study, marked changes in the pattern of
synthesis were observed at the 8-16-cell stage of development. Quantitatively, a gradual
decrease in rate of protein synthesis occurred between the zygote and the 8-cell stage and
then increased progressively to the blastocyst stage. Grealy and coworkers (1996) were
the first to actually report the amount of protein in bovine oocytes and in vivo-derived
embryos. Authors concluded that protein content of oocytes and 2-cell stage embryos was
very similar (0.126 and 0.132 ug per oocyte and embryo, respectively), higher in morula
and blastocyst stage embryos (0.183 and 0.185 μg per embryo, respectively), and even
higher for the expanded blastocyst stage embryo (0.367 μg). Also, a 160- and more than
2000-fold increase in protein content of hatched blastocysts recovered on day 13 and 16,
respectively, was observed when compared to protein content of expanded blastocysts on
8

day 8. These findings are in agreement with those reported by Frei et al. (Frei et al.,
1989) and suggest that the increase in protein content from the 2-cell stage embryo
onwards is related to the activation of the embryonic genome at the stage of 8- to 16-cell
(Camous et al., 1986; Memili et al., 1998), an event followed by a sharp increase in
protein synthesis in the embryo. The protein content of bovine oocytes and in vitroderived embryos was recently reported by Thompson and collaborators (1998). Despite
using different techniques to determine protein content in the embryo (BCA vs. Lowry
methods), the amount of protein in ova and pre-compacted stage embryos reported by
these two studies were similar. On the other hand, protein content between in vivoderived (Grealy et al., 1996) and in vitro-derived (Thompson et al., 1998) expanded
blastocysts differed between these two studies (367 ± 28 vs. 152 ± 10 ng per embryo,
respectively). However, it is worth noting that Thompson and coworkers utilized in vitroderived zona pellucida-free embryos to determine protein content, and when using zona
pellucida-enclosed expanded blastocyst, the total amount of protein was estimated to be
337 ± 58 ng per embryo. Therefore, the authors estimated that the protein content of the
zona pellucida from in vitro-derived embryos is approximately 200 ng.
In summary, data demonstrate that protein content decreases prior to compaction
and increases after compaction and during the formation of the blastocyst (Frei et al.,
1989; Thompson et al., 1998). This pattern suggests that during pre-compaction
development, levels of protein degradation are higher than protein synthesis and that net
growth is observed only after the activation of embryonic genome.
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4. Compaction and blastocyst formation
Compaction represents a key critical event for continued embryonic development.
It allows polarization and differentiation of blastomeres into two different cell
populations (by induction of cell adhesion molecules between blastomeres that enhance
cell communication and adherence) and facilitates fluid accumulation within the embryo
that directly contributes to blastocyst formation and subsequent hatching from the zona
pellucida (Watson, 1992). Compaction appears to occur in all mammalian embryos but
timing differences exist between species: mouse at 8-cell stage (Ducibella and Anderson,
1975), humans at 16-cell stage (Edwards et al., 1981), and bovine (Van Soom et al.,
1997) and rabbit (Koyama et al., 1994) at 32-cell stage.
During compaction, blastomeres adhere to and flatten against each other and
boundaries between cells cannot be recognized (Van Soom et al., 1997). Development of
the Ca++-dependent cell adhesion molecule E-cadherin allows the establishment of gap
and tight junctions leading to cellular and morphogenetic differentiation of blastomeres
(Braga, 2002). Outer blastomeres polarize and form the trophectoderm (TE), while inner
blastomeres remain apolar and generate the inner cell mass (ICM;(Koyama et al., 1994).
The inner cell mass forms the embryo proper and some extra-embryonic membranes;
whereas, trophectoderm cells will combine with ICM-derived extra-embryonic
membranes to form the fetal placenta (Schlafer et al., 2000). The increase in
interblastomeric contacts during compaction is mediated mainly by the action of Ecadherin, a Ca++-dependent cell adhesion molecule (Pratt et al., 1982; Riethmacher et al.,
1995), but also by action of microfilaments and microtubules (Pratt et al., 1981), high
intracellular levels of Ca++ (Pey et al., 1998), and activation and phosphorylation of
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proteins by protein kinase C (Winkel et al., 1990). In fact, compaction can be inhibited or
disrupted by addition of cytochalasin D (antimycotic drug that depolymerizes
microfilaments), colcemid (a derivate of colchicines, a plant toxin that inhibits
microtubule polymerization) or by culturing embryos in Ca++-free medium (Pratt et al.,
1981; Pratt et al., 1982; Reima, 1990). In addition, activation of PKC with phorbol ester
or treatment with diacylglycerides caused 4-cell mouse embryos to compact ahead of
normal timing, while PKC inhibitors prevented compaction (Winkel et al., 1990).
During compaction, the free or apical membrane surfaces of the outer cells
develop a microvillus cap with several Na+/dependent transport systems (Miller and
Schultz, 1985; Fleming and Johnson, 1988). These transport systems play a central role in
establishment of an ion concentration gradient across the epithelium that facilitates
osmotic accumulation of water into the blastocoelic space to form the nascent blastocoele
(Biggers et al., 1988). Basolateral surfaces of TE remain free of microvilli, but become
distinguished from apical surfaces by localization of tight junctions (Fleming et al.,
1989), gap junctions (Kidder, 1987), adherent junctions (Vestweber et al., 1987), and
acquisition of an active Na+/K+ ATPase pump (Watson et al., 1999).
In summary, during compaction, increase of interblastomeric contacts mediated
by several adhesion molecules (mainly E-cadherin) induces cell polarization and
differentiation of blastomeres into two cell populations, the TE epithelium and the ICM.
Moreover, the trophectoderm develops the capacity to initiate and regulate blastocoele
formation by the action of Na+/K+ ATPase enzyme (especially in the basolateral surface
TE epithelium) and the presence of tight junction at the apical part of the TE epithelium
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that prevents uncontrolled leakage of this fluid from the blastocoele cavity (Watson et al.,
1992).

5. Role of E-cadherin during embryonic development
E-cadherin has three major domains or regions: an extracellular domain
responsible for specific recognition of the same cadherin present in neighboring cells, a
transmembrane domain that spans the cell membrane, and a cytoplasmic domain that
extends into the cell and associates with cytoplasmic proteins called catenins, which in
turn bind cadherins to actin filaments in the cytoskeleton (Ivanov et al., 2001). In the
mouse, E-cadherin is expressed in the oocyte and during the early period of embryonic
genome activation (at 2-cell stage; (Vestweber et al., 1987). E-cadherin-mediated
adhesion between blastomeres initiates compaction and plays a critical role in
differentiation of the trophectoderm and morphogenesis of the mouse blastocyst (Fleming
and Hay, 1991). E-cadherin is uniformly distributed on the surface of all mouse
blastomeres during early cleavage but redistributes to cell-cell contact sites upon
activation at the 8-cell stage (when compaction begins) suggesting post-translational
regulations. In fact, E-cadherin becomes phosphorylated for the first time at compaction
(Sefton et al., 1992). In addition, homozygous null mutant mouse embryos for the Ecadherin gene initially compact (an event attributed to the presence of maternal or
oogenetic E-cadherin proteins) but then proceed to decompact, with cells becoming
apolar due to interference in the formation of apical junctional complexes (Laure et al.,
1994; Riethmacher et al., 1995). Moreover, these embryos fail to develop a normal
blastocoele cavity and do not hatch from the zona pellucida (Riethmacher et al., 1995).
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Fibroblast cells lost cell-cell contacts (Erez et al., 2004) and mouse embryos
decompacted (Reima, 1990) when exposed to antibodies directed against Ca++-dependent
molecules, further suggesting involvement of E-cadherin during compaction.
In cattle, E-cadherin is evenly distributed around cell margins of 1-cell zygotes
and cleavage stage embryos and becomes restricted to basolateral membranes of outer
cells at morula stage, while maintaining apolar distributions in the ICM (Barcroft et al.,
1998). This suggests an involvement of E-cadherin in the formation of junctional apical
complexes during the bovine compaction process. In a recent study, targeted disruption of
the E-cadherin gene in bovine preimplantation embryos by RNA interference technology
resulted in less embryos reaching compact morula or blastocyst stage (Nganvongpanit et
al., 2006). These findings indicate a critical role of E-cadherin not only during
compaction, but furthering embryonic development.

6. Role of tight junctions during embryonic development
Tight junctions are a “belt-like”, multiprotein complex around each cell and
represent a site of close intercellular adhesion including partial membrane fusion. Tight
junctions form a barrier against paracellular diffusion, generate a trans-epithelial
resistance, and allow accumulation of fluid during blastocoele formation (Biggers et al.,
1988). Tight junctions comprise several proteins (both transmembrane and cytoplasmic)
with the most important being zonula occludens 1 (ZO-1α+ and ZO-1α-; (Willott et al.,
1992)) and cingulin (Citi, 1993). Although tight junction formation does not begin until
compaction of the 8-cell stage mouse embryo (a process dependent upon E-cadherin
activation), immunoblotting of unfertilized oocytes and preimplantation mouse embryos
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showed high levels of cingulin in oocytes and early cleavage stages up to the 16-cell
(Javed et al., 1993), indicating a maternal inheritance of these transcripts and protein.
During compaction in the mouse, outer cells gradually envelope inner cells
causing ZO-1 in the inner cells to disappear. Thus, symmetrical cell contact appears to
initiate ZO-1 down regulation in the ICM lineage (Fleming and Hay, 1991). In cattle,
ZO-1 is undetectable until the morula stage when it first appears as punctuate points
between outer cells. In blastocysts, ZO-1 is localized as a continuous ring at apical points
of trophectoderm or outer cell contacts, whereas it remains undetectable in the ICM
(Barcroft et al., 1998). Miller and coworkers (2003) reported that the amount of tight
junction mRNA in in vitro-derived bovine embryos is dependent on the ability to undergo
a well-orchestrated compaction process. In this study, when blastocyst developed after a
short compaction period, expression of total tight junction mRNA was lower than in
blastocysts derived from a longer compaction process. Moreover, a dramatic increase in
ZO-1 was observed during transition from morula to blastocyst stage both in in vivo and
in vitro-derived embryos, suggesting a stage-dependent rather than a time-dependent upregulation of embryonic transcription just prior to blastocyst formation.

7. Role of the Na+/K+ ATPase pump during embryonic development
The Na+/K+ ATPase is composed of two obligatory subunits, a catalytic,
nonglycosylated α-subunit and a glycosylated β-subunit (Jorgensen, 1982). The α-subunit
is responsible for the physiological role of the enzyme (Jorgensen, 1986), while the βsubunit may facilitate processing and insertion of the α-subunit into the plasma
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membrane (Geering, 1991). These subunits are encoded by multi-gene families as four αsubunits (α1, α2, α3, α4) and two β-subunit (β1, β2) have been cloned (Kent et al., 1987).
In the mouse, this enzyme is first detected at the late morula stage within the
cytoplasm of each blastomere; but when cavitation begins, its distribution changes
dramatically to a ring encircling the blastocoele, and restricted to the basolateral cell
margins (Watson and Kidder, 1988). Moreover, northern hybridization experiments have
detected transcripts for only the α1-subunits in all stages of mouse preimplantation
development (Watson et al., 1990). In contrast, in vitro-produced bovine embryos
expressed multiple α- and β-subunits of this enzyme throughout early development (Betts
et al., 1998). Furthermore, the bovine Na+/K+ ATPase enzyme is more sensitive to effects
of ouabain (an inhibitor of Na+/K+ ATPase) than the one present in murine embryos
(Betts et al., 1998). In addition, Na+/K+ ATPase transcripts were detected in the ICM
cells and trophectoderm cells of bovine blastocysts (Wrenzycki et al., 2003). Wrenzycki
et al. (2003) investigated gene expression directing bovine blastocyst formation in TE
and ICM cells and reported that Na+/K+ ATPase, E-cadherin, ZO-1 and glucose
transporter-3 transcripts were higher in TE cells when compared to ICM cells. In
contrast, desmocollin II and glucose transporter-1 and -4 were more abundant within
ICM cells. These results demonstrate a specific gene expression pattern between these
two cell lines in the early embryo regulating preimplantation development.

8. Role of gap junctions during embryonic development
Gap junctions are channels present in opposing plasma membranes of neighboring
cells (Kidder and Wintergaher, 2001). The cell membranes come close together, but are
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separated by 2-4 nanometers. These junctions are composed of at least 13 different
proteins called connexins (Bruzzone and Goodenough, 1996; De Sousa et al., 1997);
however, several studies identified connexin 43 as the most important gap junctional
protein expressed in mouse (De Sousa et al., 1993; Valdimarsson and Kidder, 1995),
bovine (Wrenzycki et al., 1996; Wrenzycki et al., 1999), and rat (Reuss et al., 2002)
preimplantation embryos.
Intercellular communication through gap junctions is believed to be essential for
cellular growth, differentiation and development (Warner, 1987; Zhang and
Thorgeirsson, 1994). At the plasma membrane, six copies of the same connexin form a
hexagonal ring-shaped channel called connexon. Connexons in adjacent cell membranes
align together to form a hydrophilic channel that allows direct passage of molecules up to
1 kDa such as ions, cyclic AMP, Ca++, and inositol trisphosphate (IP3) between cells, and
thereby coordinate metabolic and electrical activities.
In mouse, assembly of functional gap junctions is first observed during
compaction in 8-cell stage embryos (Lo and Gilula, 1979; McLachlin et al., 1983) and
represents a critical step for maintenance of compaction and subsequent blastocyst
formation (Lee et al., 1987; Bevilacqua et al., 1989). Injection of gap junction antisense
RNA to 2- and 4-cell mouse embryos reduced the percentage of compacted embryos to
less than 20%, while 90% of uninjected embryos compacted (Bevilacqua et al., 1989).
Also, when the same antisense was injected to 8-cell mouse embryos, only 5% of the
embryos developed to blastocyst stage, while blastulation occurred in 90% of control
embryos. Similarly, injection of gap junction antibodies inhibited dye transfer and
dramatically reduced electrical coupling of 8-cell mouse embryos (Lee et al., 1987).
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Moreover, preimplantation mouse embryos deficient in connexin 43 retained the capacity
for cell-to-cell transfer of fluorescent dye (dye coupling), but at a severely reduced dye
coupling (De Sousa et al., 1997).
Literature on intercellular communication through gap junctions in early bovine
embryos is limited. Utilizing polymerase chain reaction (PCR), Wrenzycki and
colleagues (1996) reported that transcripts for connexin 43 were present in immature
oocytes and in all developmental stages of in vitro-produced embryos up to the morula
stage. In contrast, only in vivo-derived morula and blastocyst stage embryos expressed
connexin 43. These findings agree with reports from Boni et al. (1999) that demonstrated
diffusion of dye between ICM cells of in vivo-derived morula stage embryos and ICM
cells of in vitro-produced blastocyst stage embryos. Moreover, junctional conductance
was higher in in vivo embryos than in in vitro embryos, with isolated ICM cells from both
groups of embryos showing greater conductance compared to intact blastocyst. Higher
junctional conductance was also correlated with higher density of gap junctions in in
vivo-derived embryos than their in vitro counterparts. Prather and First (1993) also
reported that in vivo-derived morula and blastocyst stage embryos showed dye transfer
indicating the existence of gap junctions. However, in vitro-produced morula and
blastocyst stage embryos did not show spreading of dye. Differences in dye transfer
between Boni et al. (1999) and Prather and First (1993) studies may be explained by the
fact that in the later, injection of dye to in vitro embryos was only performed on TE cells,
and as Boni et al. (1999) demonstrated, no transfer of dye was observed in TE cells
derived from in vitro embryos.
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9. The zona pellucida, structure and functions
The zona pellucida (ZP) is an extracellular matrix surrounding growing oocytes,
ovulated oocytes, and early stage embryos (Baker, 1972). The ZP exerts several
important functions such as binding to spermatozoa in a specie-specific manner,
induction of sperm acrosome reaction, blocking polyspermy, preventing the dispersion of
blastomeres during preimplantation development, facilitating the passage of the embryo
through the oviduct, and protecting the embryo during early stages of development
(Wassarman, 1990, 1990; Epifano and Dean, 1994).
The majority of data generated on the structure and function of the ZP were
obtained from studies performed in mouse and has been used as a model for other
species. The mouse ZP is approximately 7 μm thick, and consists of three glycoproteins
called mouse (m) ZP1, mZP2, and mZP3, with molecular weight of approximately 200,
120, and 83 kD, respectively (Bleil and Wassarman, 1980). All these ZP glycoproteins
are exclusively secreted by the growing oocyte until time of ovulation (Bleil and
Wassarman, 1980). These glycoproteins are organized in a specific manner within the
extracellular matrix. Dimers composed of mZP2 and mZP3 polymerize into long
filaments that constitute the ZP. The mZP1, a dimer of identical polypeptides, serves as
the cross-linker between filaments. Ovaries from homozygous null female mice for mZP3
(mZP3-/-) contained growing oocytes without ZP, while oocytes from heterozygous null
females (mZP3+/-) had a ZP half the thickness of those from wild-type female mice (Liu
et al., 1996; Rankin et al., 1996). Homozygote female mice for mZP3 exhibited normal
reproductive behavior, but failed to become pregnant after mating with fertile wild type
male mice.
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In addition, mZP3-/- female mice carrying a human ZP3 (hZP3) transgene
possessed a thick ZP that consisted of mZP1, mZP2 and hZP3 (Rankin et al., 1998). In
addition to the structural role of mZP3 during ZP formation, the mZP3 serves also as a
receptor for sperm (Bleil and Wassarman, 1980). Only purified mZP3 binds specifically
to heads of acrosome-intact sperm and prevents sperm from binding to ovulated oocytes
in vitro (Bleil and Wassarman, 1980). On the other hand, mZP3 from fertilized oocytes or
early embryos did not prevent binding of sperm to the ZP of ovulated oocytes in vitro
(Bleil and Wassarman, 1980), which suggests that protein changes in ZP3 after
fertilization inhibit further binding of sperm to the ZP. Acrosome intact sperm recognize
and bind to specific O-linked oligosaccharides located on serine residues (serine 332 and
334) near the carboxy terminus of mZP3 polypeptide (Kinloch et al., 1995). Moreover,
certain oligosaccharides inhibited binding of mouse sperm to oocytes in vitro (Litscher et
al., 1995) indicating that binding of sperm to oocytes is a carbohydrate-mediated event.
The mZP3 also triggers the acrosome reaction in sperm (Bleil and Wassarman, 1983),
which allows sperm to penetrate the zona pellucida and fuse with the oocyte’s plasma
membrane. During acrosome reaction, the sperm remains bound to the ZP by binding to
mZP2 (Bleil et al., 1988).
Zona pellucida glycoproteins are found in ZP of oocytes from virtually all
mammalian species, from mice to humans (Wassarman et al., 1999; Wassarman, 1999)
with a remarkable similarity in amino acids homology between species. In bovine, the ZP
is composed of only a few highly modified glycoproteins; bovine (b) ZP1, bZP2, bZP3α,
bZP3β, and bZP4 (Topper et al., 1997). The sperm receptor activity is attributed to ZP3α,
while ZP2 serves as a secondary receptor for acrosome-reacted sperm. After sperm-egg
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fusion, enzymes released by the cortical granules during the cortical reaction convert ZP2
and ZP3 to ZP2f and ZP3f, respectively. These modifications inhibit further fusion of
sperm with the oocyte’s plasma membrane, a phenomenon called block of polyspermy
(Kopf, 1990). In addition to ZP glycoproteins, passage of an early embryo through the
oviduct allows the incorporation of several other proteins secreted by the oviductal
epithelium (Buhi et al., 2000; Buhi, 2002).
Contrary to the mouse, where the growing oocyte is the only source of zona
glycoproteins (Flechon et al., 1984), investigations in other species such as human
(Grootenhuis et al., 1996), monkey (Grootenhuis et al., 1996), rabbit (Grootenhuis et al.,
1996), dog (Tresoriero, 1981), pig (Sinowatz et al., 1995) and cow (Kolle et al., 1998)
have shown that both the oocyte and the follicle cells (corona radiate cells) contribute to
the synthesis of ZP glycoproteins. These finding have been supported by in vitro cell
culture of granulosa cells that were able to secrete ZP glycoproteins (Skinner et al.,
1984). During follicular development in the bovine ovary, the ZP3β protein and its
mRNA are primarily localized in the oocytes of primordial and primary follicles
(Sinowatz et al., 1995; Kolle et al., 1998). In secondary follicles, both the oocyte and
granulosa cells express ZP3β protein and transcripts (Sinowatz et al., 1995; Kolle et al.,
1998). In tertiary and pre-ovulatory follicles, both protein and transcripts are found in the
cytoplasm of granulosa cells (Sinowatz et al., 1995; Kolle et al., 1998). In addition,
investigations in fetal bovine ovaries have shown that ZP proteins are synthesized by the
oocyte and granulosa cells during prenatal development (Totzauer et al., 1998).
When visualized by scanning electron microscopy (SEM), the mammalian ZP is
found to be composed of a network dispersed with numerous pores (Dudkiewicz and
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Williams, 1977) and with morphologically dissimilar internal and external surfaces. The
external surface displays a fenestrated lattice-like appearance and the internal surface
shows a regular rough appearance (Phillips and Shalgi, 1980). When pores are compared
among species, the largest pores are observed in the ZP of the rabbit and the cat, and the
smallest in the cow. The pores are largest at the outer surface of the ZP but decrease in
size centripetally (Dudkiewicz and Williams, 1977). Vanroose and coworkers (2000)
studied the outer ZP surface of bovine oocytes, zygotes, 8-cell stage and morula stage
embryos. In this study, the outer ZP surface of bovine oocytes and morulae showed a
rough and spongy appearance with numerous pores. On the other hand, the outer ZP
surface of zygotes was found to have a smooth, melted appearance with only a few pores
and 8-cell stage embryos presented both surface patterns. The mean number of pores was
1511 in oocytes, 1187 in zygotes, 1658 in 8-cell stage embryos, and 3259 in morulae,
with mean diameters of 182, 223, 203, and 155 nm, respectively. In the same study, the
ability of fluorescent microspheres of 40-50 nm and 180-200 nm to traverse the ZP was
evaluated. Authors concluded that for all stages evaluated, the smallest beads were
detected half way through the thickness of the ZP, whereas the biggest beads remained
only at the outer surface of the ZP.

10. Hatching process
In cattle, accumulation of fluid (between days 8 and 10 after fertilization) within
the blastocoele cavity in the blastocyst distends the zona pellucida (ZP), which becomes
gradually thinner until it ruptures allowing escape of the blastocyst by protrusion through
the opening in the ZP (Flechon and Renard, 1978; Massip and Mulnard, 1980).
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Accumulation of fluid within the blastocoele cavity is achieved by a sodium
concentration gradient created in the blastocoele cavity by the presence and function of
the Na+/K+-ATPase pump (Biggers et al., 1988) at the basolateral surface of the
trophectoderm epithelium. Additionally, the presence of a junctional apical complex
(formed by tight junction at the apical part of the TE epithelium) prevents uncontrolled
leakage of this fluid from the blastocoele cavity (Watson et al., 1992; Bavister, 1995).
In hamster and mouse embryos, hatching results from degradation of the ZP by
enzymes originated from the embryo and/or the uterus (Gordon and Dapunt, 1993;
Gonzales and Bavister, 1995). In fact, hatching of in vitro-produced mouse blastocyst has
been related to a trypsin-like proteinase associated with cells of the trophectoderm
(Perona and Wassarman, 1986). In the cow, there is no evidence of an enzymatic
mechanism during hatching since zona pellucida-intact embryos, as well as empty ZP,
can be found from uterine flushings up to day 16 after ovulation (Betteridge et al., 1980).
These findings suggest that in the cow, hatching of the fully expanded bovine blastocyst
occurs through an increase in hydrostatic pressure in the blastocoele cavity which is
followed by rupture of the ZP.
Several studies during in vitro blastocyst expansion and hatching have observed
one or more partial or total collapse(s) of the blastocoele cavity followed by re-expansion
of the blastocoele. This pulsatile activity has been observed in various species including
rabbit (Lewis and Gregory, 1929), mouse (Cole, 1967), and cow (Massip and Mulnard,
1980). The origin and possible roles of these collapses are unknown; however, excessive
pulsatility might be related with poor embryo viability due to the fact that blastocyst
exhibiting frequent collapses failed to hatch (Massip and Mulnard, 1980). In a recent
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study (van Heule et al., 2001), the effect of serum supplementation on pulsatile activity
and hatching of in vitro produced bovine blastocyst was investigate by time-lapse
cinematography. Addition of serum increased pulsatile activity before ZP rupture,
reduced the time of hatching and increased hatching rates when compared to embryos
cultured in the same medium but without serum supplementation. Moreover, pulsatile
activity was not involved in the hatching process due to the fact that blastocyst showing
no collapses hatched. Finally, hatching occurred at various times post insemination
(average of 153h 35 min ± 1h 59 min) and at various embryo diameters (ranging from
179 to 235 μm).

11. Developmental differences between in vivo and in vitro embryos
Before making inferences about similarities and differences between in vitro and
in vivo-derived embryos, it worth noting that literature cited to prepare this discussion can
be considered “old”, with the majority of these publications published in the 90’. Since
then, several changes on in vitro development of bovine embryos have occurred to more
closely resemble the events occurring during in vivo development of bovine embryos in
an effort to increase the quality of in vitro-derived embryos.
The percentage of putative zygotes reaching the blastocyst stage after in vitro
production (IVP) of embryos is only 20 to 30% (Thompson and Duganzich, 1996). In
addition to this poor developmental capacity, in vitro-derived embryos present lower
quality than those derived from in vivo. In an attempt to determine such differences, Van
Soom and Kruif (1992) cultured in vivo-derived zygotes and 2-cell stage embryos and in
vitro-derived putative zygotes under identical conditions. In this study, in vivo-derived
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zygotes and early embryos cleaved and developed better than in vitro-derived putative
zygotes (84.3 vs. 62% cleavage and 69 vs. 35% development, respectively). Moreover, in
vivo-derived embryos compacted better and presented better blastomere morphology
(rounded vs. square and swollen) than in vitro counterparts. In addition to this, Iwasaki
and Nakahara (1990) reported that allocation of cells to the inner cell mass is lower at the
blastocyst stage for in vitro-derived embryos. In fact, Van Soom et al. (1997)
demonstrated that rapid transition between morula to blastocyst stage of in vitro-derived
embryos is responsible for lowering the numbers of cells at the inner cell mass of the
embryo. To the contrary, the longer transition from morula to blastocyst stage of in vivoderived embryos allows sufficient time for allocation of inner cells to the inner cell mass
of the embryo.
Other differences between in vivo and in vitro embryos include chromosomal
abnormalities, morphology under electron microscopy, embryo metabolism, gene
expression and survival after handling and freeze/thawing techniques. Conditions utilized
during in vitro production of embryos affected the incidence of chromosomal
abnormalities, from 7-10% in in vivo- to 15% in in vitro-derived embryos (Kawarsky et
al., 1996). Moreover, under electron microscopy, in vitro-produced embryos were
characterized by a lack of desmosomal junctions, a reduction of surface microvilli, an
increase in the number of lipid droplets, mitochondrial degeneration, and cytoplasmic
vacuolation (Shamsuddin and Rodriguez-Martinez, 1994; Rizos et al., 2002). Compared
with their in vivo counterparts, in vitro-produced embryos tend to have darker cytoplasm
and a lower buoyant density as a consequence of their higher lipid content (Pollard and
Leibo, 1994) and a more fragile zona pellucida (Duby et al., 1997). With regard to
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embryo metabolism, ATP production, oxygen uptake and glucose uptake between in vivo
and in vitro-derived embryos appear to be the same (Thompson et al., 1996). On the other
hand, glucose oxidation (Thompson et al., 1991) and amino acid uptake (Partridge and
Leese, 1996) for in vitro-derived embryos appeared to be lower than in vivo-derived
embryos. The quality and cryotolerance of in vivo-derived embryos are higher than
embryos produced in vitro. These differences may be explained by differences in gene
expression and lipid content between these two groups of embryos.
Recent studies have shown that development of in vitro-derived embryos depends
upon developmental competence of the oocyte (Rizos et al., 2002); however, the postfertilization culture environment is known to be the most important factor determining
quality of resulting embryos (Rizos et al., 2002; Rizos et al., 2003). Several studies have
reported expression patterns of developmentally competent genes in preimplantation
bovine embryos (Wrenzycki et al., 1996; Wrenzycki et al., 1998, 1999; Lazzari et al.,
2002; Rizos et al., 2002; Rizos et al., 2002; Wrenzycki et al., 2003; Mohan et al., 2004;
Tesfaye et al., 2004; El-Halawany et al., 2005); however, the end point of these studies
has generally been measured in blastocyst stage embryos. Lonergan et al. (2003), in an
attempt to determine temporal divergence in mRNA expression of in vitro and in vivocultured bovine embryos, reported that changes in gene expression are strongly
influenced by the culture environment and that changes in the amount of mRNA in
blastocyst stage embryos are a consequence of lowered transcription earlier in
development. In a similar study, Tesfaye et al. (2004) also reported temporal divergences
in mRNA between in vivo and in vitro-derived bovine embryos. These findings are in
agreement with those from Rizos et al. (2002; 2003), where culture medium of in vitro
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produced embryos determined quality of resulting embryos measured in terms of their
cryotolerance and relative abundance of transcripts. Moreover, Lazzari et al. (2002)
demonstrated that in vitro culture of bovine embryos using animal proteins (bovine serum
albumin, BSA) alters kinetics of embryo development (greater amount of cells and
overall size), the expression of developmentally important genes, and when transferred to
suitable recipients, resulted in higher birth weight of calves compared to embryos
produced in vivo. Furthermore, when embryos were cultured in medium without BSA
(replaced by polyvinyl alcohol, PVA), gene expression patterns resembled that of in vivoderived embryos. Therefore, alterations in gene expression of in vitro-produced embryos,
caused by the culture environment, are probably responsible for lowering the quality of
these embryos when compared to the quality of in vivo-derived embryos.

12. Synthesis of prostaglandins
Prostaglandins are involved in several physiological processes such as
inflammation, production of pain and fever (Seibert et al., 1994; Blatteis and Sehic,
1997), control of blood vessel tone and arterial blood pressure (Nett et al., 1976),
luteolysis (Goding, 1974), muscle growth and differentiation (Horsley and Pavlath,
2003), and blood clotting (Moncada and Vane, 1981). With exception of red blood cells,
prostaglandins are synthesized and released by all mammalian cells and tissues.
However, unlike other hormones, prostaglandins are not stored in cells but are produced
and released immediately after synthesis (Bito, 1975).
Phospholipase A2 (PLA2) enzymes catalyze hydrolysis of the sn-2 position of
membrane glycerophospholipids to liberate arachidonic acid (AA), a precursor of
26

prostaglandins, tromboxane A2, and leukotrienes. So far, at least 19 enzymes that possess
PLA2 activity have been identified in mammals (reviewed by (Murakami and Kudo,
2004). Since arachidonic acid contains 20 carbon atoms, prostaglandins are referred as
eicosanoids.
The formation of PGF2α begins with release of the precursor of all prostaglandins,
arachidonic acid (AA), from the sn-2 position of membrane phospholipids principally by
the action of the cytosolic, high molecular weight, calcium-dependent phospholipase A2
(cPLA2; (Flint et al., 1986), but also by the action of phospholipase C (PLC),
phospholipase D (PLD), and mono- and diacy-glycerol lipases (Flower and Blackwell,
1976; Irvine, 1982; Kozawa et al., 1997; Kozawa et al., 1997). Cleavage of AA from
membrane phospholipids is the rate-limiting step in prostaglandin synthesis. Several
phospholipases A2 (PLA2s) can release AA from membrane phospholipids (as reviewed
by (Khan et al., 1995; Capper and Marshall, 2001). These PLA2s are basically divided in
two groups: 1) Low molecular weight PLA2s (the largest group): are secreted to the
extracellular space and their activity depends on high levels of calcium. Their functions
are not very well known with the exception of the IIA and IB PLA2s. Phospholipase IIA
has direct bactericidal effect on gram-negative bacteria, whereas PLA2IB (also called
pancreatic PLA2) participates in lipid digestion. The other group 2) High molecular
weight PLA2s are constituted by intracellular PLA2s, that are also divided in calciumdependent (cPLA2α or IVA cPLA2, cPLA2β or IVB cPLA2) and calcium-independent
PLA2 (VIA iPLA2 and IVC cPLA2)
Arachidonic acid released by the action of PLA2s is converted to prostaglandin H2
(PGH2) by the action of cyclooxygenase enzymes-1 or -2 (COX-1 and COX-2) at the
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membrane of the endoplasmic reticulum (Smith and Dewitt, 1996) or at the nuclear
envelope (Parfenova et al., 2001). Cyclooxygenase-1 is a constitutive enzyme found in
almost all cells (O'Neill et al., 1994), whereas COX-2 is an inducible form in response to
inflammatory reactions, hormonal and environmental stimulus (Smith and Dewitt, 1996).
Conversion of AA to PGG2 is performed in two sequential enzymatic steps: oxygenation,
which converts free arachidonic acid to the unstable intermediate PGG2, followed by a
peroxidation that converts PGG2 to PGH2 (Smith and DeWitt, 1996). These two
enzymatic reactions (oxygenation and peroxidation) are catalyzed by the enzymes
cyclooxygenase-1 and –2 (COX-1 and COX-2). Finally, PGH2 is transformed into PGF2α
by tissue-specific prostaglandin F2α synthase (Watanabe et al., 1985). Following its
synthesis, PGF2α is transported out of the cell by a prostaglandin transporter (Chan et al.,
1998) where it exerts an autocrine or paracrine function through its G protein coupled
receptor. Catabolism of PGF2α is accomplished by the enzyme prostaglandin 15dyhydrogenase (PGDH), which converts PGF2α into the inactive PGF2α metabolite,
PGFM (Keirse et al., 1978).
Different specific enzymes, whose presence varies depending on the cell type,
mediate formation of the D, E, I, and F series from PGH2 in different tissues. Synthesis of
prostaglandins can be blocked by administration of nonsteroidal anti-inflammatory drugs
(NSAIDs) such as aspirin, flunixin meglumine, indomethacin and phenylbutazone and by
steroidal anti-inflammatory drugs like hydrocortisone, prednisone and prednisolone.
Nonsteroidal anti-inflammatory drugs act through inhibition of COX-1 and COX-2 (Vane
and Botting, 1996), while steroidal anti-inflammatory drugs interfere with mobilization of
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arachidonic acid from the plasma membrane by inhibition of phospholipase A2 (Rothhut
and Russo-Marie, 1984).

13. Mechanism of action of prostaglandin F2α
Prostaglandin F2α interacts with its G protein coupled receptor at the cell
membrane and activates Gq Protein/phospholipase C (PLC-β)/Calcium release/Protein
Kinase C (PKC) signaling pathway (Wiltbank et al., 1989; Wiltbank et al., 1990;
Abramovitz et al., 1994; Sugimoto et al., 1994; Sales et al., 2004). G protein receptors
contain 3 subunits called α, β, and γ (Findlay et al., 1993). The β and γ subunits remain
together and are usually referred as the Gβγ subunit, whereas the α subunit is referred to
the Gα subunit as reviewed by Findlay et al. (1993). Following PGF2α binding to its Gq
protein-coupled receptor (Lee et al., 1987), the Gα subunit suffers a conformational
change that allows exchange of GDP for GTP and dissociation of the Gα from the Gβγ
subunit. Next, the Gα subunit binds to PLC-β causing its activation. After activation of
PLC-β, the intrinsic GTP-ase activity of the Gα subunit hydrolyzes bound GTP to GDP
and dissociates from PLC-β allowing re-association of the Gα subunit with the Gβγ
subunits (inactive Gq form). Next, PLC-β cleaves phosphatidyl inositol 4,5 bisphosphate
(PIP2) into two second messengers: diacylglycerol (DAG), that remains associated to the
plasma membrane and inositol 1,4,5 trisphosphate (IP3) that diffuses to the cytoplasm.
Inositol trisphosphate releases calcium from the endoplasmic reticulum to the cytosol
(Berridge, 1993).
The increase of intracellular calcium levels recruits PKC to the cell plasma
membrane where DAG causes its activation. Protein Kinase C phosphorylates several
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other proteins involved in cellular growth and metabolism. Exposure of bovine luteal
cells and osteoblasts to PGF2α activates Raf/MEK/MAPK signaling cascade (Chen et al.,
1998). Mitogen activated protein kinases (MAPK) form homodimers that translocate to
the nucleus where they regulate activity (through phosphorylation) of many nuclear
transcription factors such as TCF or SRF (reviewed by (Hunter, 2000). Phosphorylated
TCF and SRF form a transcription factor complex that binds to SRE in DNA and
stimulate gene transcription of c-fos and c-jun genes (Chen et al., 2001). In addition, Gq
protein may not be the only G-protein involved in induced MAPK activation, since
studies involving pertussis toxin (a selective inhibitor of G-protein Gi) demonstrated
inhibition of PGF2α -dependent MAPK stimulation by this toxin (Melien et al., 1998). In
agreement with this, Gi βγ subunits mediated activation of MAPK in PGF2α -stimulated
uterine myometrial cells (Melien et al., 1998). Mitogen activated protein kinases were
directly activated through Ras or indirectly activated by the formation of the Shc, Grb2
and SOS complex leading to activation of Ras followed by activation of the
Raf/MEK/MAPK signaling cascade. Furthermore, PGF2α-induced proliferation of
neoplastic human endometrial cells by activating MAPK signaling via PLC-β and transactivation of the epidermal growth factor receptor (EGFR; (Sales et al., 2004). Lastly, the
increase in cytosolic calcium by IP3 and activation of PKC can lead to activation of other
protein kinases such as PI3K, p38 and Junk, which can also mediate cellular responses.
The bovine CL represents an excellent model for understanding the mechanisms
of action of PGF2α. Protein Kinase C is believed to mediate many of the antisteroidogenic
actions of PGF2α in large luteal cells (McGuire et al., 1994). In addition to this, PGF2α
may interfere with ability of LH to activate PKA, an enzyme needed for phosphorylation
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and stimulation of other key enzymes in the luteal steroidogenic pathway, such as
cholesterol esterase (hydrolyzes the stored cholesterol) and steroidogenic acute regulatory
protein (StAR), which transports cholesterol to the mitochondria (Garverick et al., 1985).
In contrast to early signaling events, downstream signals in response to PGF2α are poorly
understood. Chen et al. (1998) reported that PGF2α activates the Raf/Mek1/mitogenactivated protein kinase (MAPK) signaling cascade in bovine luteal cells. Therefore,
signals on the cell surface may be responsible for transcription of luteal genes.
Prostaglandin F2α promotes apoptosis in luteal cells by activation of endonucleases after
influx of Ca++ from intracellular stores (Juengel et al., 1993). Also during luteolysis in
cattle, mRNA encoding Bax (a pro-apoptotic gene) is elevated resulting in an increased
ratio of Bax to Bcl-2 (anti-apoptotic gene), an event consistent with Bax-mediated
apoptosis (Rueda et al., 1997). Prostaglandin F2α induces apoptosis in luteal cells by
generation of oxygen radicals such as superoxide anion, hydroxyl radical and hydrogen
peroxide (Riley and Behrman, 1991; Carlson et al., 1993). Exposure of rat luteal cells to
these oxidants resulted in oxidation and loss of fluidity in cellular membranes (Sawada
and Carlson, 1991). Decreased membrane fluidity affects cellular function including
receptor binding and membrane-bound enzyme activity as demonstrated by Wu et al.
(1992), who suggested that superoxide radical production inhibited LH stimulation of
cyclic AMP and decreased activity of protein kinase A. In pigs, PGF2α depleted the CL
of vitamin C, a natural antioxidant that prevents oxygen radical formation (Petroff et al.,
1999).
Prostaglandin F2α is a potent, bioactive compound. As such, its production and
metabolism must be tightly regulated. The lungs appear to play an important role in
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inactivating prostaglandins. In the ewe, PGF2α in the blood stream has a half-life of less
than 1 min, since 99% of it is metabolized to 13, 14-dihydro-15-keto-PGF2α (PGFM) in a
single passage through the lung (Hansel and Dowd, 1986). In the cow, only 16% of
PGF2α remained in the blood after three passages through the lung (Davis et al., 1984).

14. Prostaglandin F2α receptor
Prostaglandin F2α receptors (FPr) have been cloned from cattle (Sakamoto et al.,
1994), sheep (Graves et al., 1995), mouse (Sugimoto et al., 1994), rat (Kitanaka et al.,
1994) and human (Abramovitz et al., 1994) cDNA libraries. In the cow and ewe, the
clones encode for 362 amino acids residues in the open reading frame (Sakamoto et al.,
1994; Graves et al., 1995); while in mouse and rat, FPr have 366 amino acids (Kitanaka
et al., 1994; Sugimoto et al., 1994) and human FPr consist of 359 amino acids
(Abramovitz et al., 1994). The molecular weight of the FPr is similar between species,
with estimated molecular weights ranging from 40 (humans) to approximately 41 KDa
(bovine). The hydropathy profile indicates that the deduced amino acid sequence consists
of seven hydrophobic segments, representing seven transmembrane helices, a structure
common to known prostanoids receptors and other G protein-linked receptors. The amino
acid sequences of FP receptors are very similar between different species. For example,
the bovine FPr (Sakamoto et al., 1994) shares 98% homology with the ovine FPr (Graves
et al., 1995), 86% with the human (Abramovitz et al., 1994), 80% with the mouse FPr
(Sugimoto et al., 1994), and 78% with the rat FPr (Kitanaka et al., 1994). Sequence
homology between species is highly conserved in the transmembrane domains of the FPr
protein. In contrast, the NH2-terminal and COOH-terminal regions show considerable
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sequence diversity. The NH2-terminal region contains two potential N-glycosylation sites
as observed with other members of the G protein coupled receptor family (Hubbard and
Ivatt, 1981). Several serine and threonine residues, potential phosphorylation sites for
protein kinase C, are commonly conserved in the COOH-terminal region or in the second
intracellular loop (Sakamoto et al., 1994). Sequence comparisons of the FPr and other
members of the prostanoids receptor family reveal significant homologies between them.
For example, the bovine FPr shares 34, 33, and 36% amino acid sequence homology
with the human, mouse, and bovine TXA2 receptors, respectively (Sakamoto et al.,
1994). Similarly, the bovine FPr shares 31 and 32% homology with the bovine and
mouse EP3 receptors (Sakamoto et al., 1994). It is worth noting that these homologies are
mostly localized to transmembrane domains, particularly domain VII.
In order to elucidate the mechanisms of receptor-ligand interactions at the
molecular level, Sakamoto and coworkers (1995) constructed a model for the bovine FPr
based on its amino acid sequence, the known helical arrangement of rhodopsin (a Gprotein coupled receptor; (Findlay et al., 1993), and a model of the human TXA2 receptor
(Yamamoto et al., 1993). The authors concluded that the ligand binding pocket of the FPr
includes argenine-291 and a large hydrophobic pocket. The carboxylic acid group of
PGF2α may interact with arginine-291. The C-9 and C-11 hydroxyl groups of the PGF2α
may interact with the serine and threonine residues in the transmembrane domains III and
VII, respectively. Another amino acid, histidine-81, in the transmembrane domain II, may
also be important for PGF2α binding as shown in transfection studies with mutant rat FPr
expressed in COS-7 cells (Rehwald et al., 1999). This may be explained in part by the
close proximity of histidine-81 to arginine-291 and also by the ability of histidine as an
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hydrogen bond donor (Rehwald et al., 1999; Anderson et al., 2001). Cysteine residues
(Cys-109 and Cys-186) in the first and second extracellular loops of the FPr are likely to
form a disulfide bond that stabilizes the protein structure (Probst et al., 1992; Abramovitz
et al., 1994; Lake et al., 1994). These two cysteines are highly conserved among all
prostanoids receptors and many other G-protein coupled receptors (Probst et al., 1992).

15. Gene structure and regulation of the FPr
The gene size of the FPr is approximately 10, 11 and 40 kilobases in humans,
mouse and cow, respectively (reviewed by Anderson et al., 2001). The FPr gene is
located in chromosome 1 in humans (Duncan et al., 1995) and near the gene for
prostaglandin E receptor-subtype 3 in chromosome 3 in mice (Ishikawa et al., 1996). The
exon/intron organization of the FPr gene is conserved among humans (Betz et al., 1999)
and cattle (Ezashi et al., 1997).
All known members of the prostaglandin receptor family have similar
organization of exons and introns (Ogawa et al., 1995) and support the idea of a common
origin from a single ancestor gene. In humans and cattle, the FPr gene contains three
exons and 2 introns with translated regions localized at exons 2 and 3 (Ezashi et al., 1997;
Betz et al., 1999). The first exon is the smallest (164 and 194 base pairs in humans and
cattle, respectively) and includes most of the 5’ untranslated region. The second exon
(approximately 870 base pairs for both species) contains a small fraction of untranslated
region and the majority of translated region for the receptor. The third and largest exon
(1459 and 3977 base pairs in humans and cattle, respectively) includes the remainder of
the translated region and a large untranslated region.
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Multiple transcription initiation sites have been identified in mouse and bovine
FPr gene. In the mouse, the major transcription site is located at the 5’ end of exon 1, 232
bp upstream of the ATG that marks the translation start site. In the bovine, multiple
transcription initiation sites were identified in exon 1. In addition, other minor
transcription initiation sites were identified in intron 1 (reviewed by (Anderson et al.,
2001).
Two potential promoter regions were identified in the bovine FPr gene (Ezashi et
al., 1997). A 1.6-kb region upstream of exon 1 contained sequences for the transcription
factors: TRE/AP-1 (TPA-responsive element/activator protein-1), NF-IL6 (nuclear
factor-interleukin 6), Sp 1, and GCF (GC binding factor). The second potential promoter
in intron 1 contained sequences for Sp 1, TRE/AP-1, CRE (cyclic AMP-responsive
element), NF-IL6, and AP-2 (activator protein-2) as well as CAAT-like and TATA-like
boxes (Ezashi et al., 1997). The activities of these two promoters were investigated by
Ezashi et al. (1997) after transfecting bovine luteal cells with these promoters linked to a
reporting luciferase gene. Treatment of transfected cells with TPA (a phorbol ester
known to activate protein kinase C), but not with forskolin (an activator of protein kinase
A), resulted in transcriptional activation of the luciferase gene. It is well known that TPA
directly activates protein kinase C (Comb et al., 1986) and that PKC can modulate the
activity of nuclear transcription factors such as AP-1, which can increase gene expression
by binding to TRE. In contrast to the findings of Ezashi and coworkers (1997), Tsai and
colleagues (1998) reported that phorbol ester and forskolin decreased and increased FPr
mRNA concentration in ovine luteal cells, respectively. These results also agreed with
several other studies (Sakamoto et al., 1995; Juengel et al., 1996; Mamluk et al., 1998;
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Hoyer et al., 1999) and suggest that additional regions of the genome are needed to
regulate transcription of the FPr gene.

16. Messenger RNA for FPr
Several studies have identified expression of FPr mRNA using Northern Blot
hybridization and polymerase chain reaction techniques. Although a great variety of
tissues express FPr mRNA in ovine, the steady-state concentration of FPr was highest in
the corpus luteum with quantities of FPr mRNA at least 100-fold greater than any other
tissue (Tsai et al., 1998). In the corpus luteum, mRNA coding for the FPr is localized
mostly on large luteal cells of bovine and ovine mid cycle corpora lutea (Fitz et al., 1982;
Juengel et al., 1996). In fact, Tsai and coworkers (1998) revealed that the concentration
of FPr mRNA was greater in large luteal cells compared with small luteal cells. Large
luteal cells contained 7,314 ± 829 copies of FPr mRNA per cell, whereas small luteal
cells contained 226 ± 54 copies per cell.
Expression of FPr mRNA in the corpus luteum was shown to progressively
increase during the estrous cycle, but was markedly reduced upon luteal regression
(Sakamoto et al., 1995). In addition, constant amounts of FPr mRNA were observed in
early and middle pregnant corpus luteum, with a significant reduction by late pregnancy
(Sakamoto et al., 1995). The expression of FPr mRNA was decreased by treatment of
ewes with PGF2α or by treatment of large luteal cells with PGF2α in vitro (Tsai et al.,
1998). Therefore, mRNA encoding FP receptor appears to be downregulated by its
homologous ligand. In fact, the number of FPr in corpus luteum from non-pregnant sheep
has been shown to decrease at the time of luteolysis (Wiepz et al., 1992). Several other
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studies have shown a decrease of FPr after PGF2α administration or natural luteolysis in
cattle (Sakamoto et al., 1995), ovine (Hoyer et al., 1999), and pigs (Estill et al., 1995). In
contrast, the FPr mRNA was increased after treatment of rats with a PGF2α analogue
(Olofsson et al., 1996), which will indicate specific species differences in the regulation
of the FPr mRNA.

17. Prostaglandin F2α receptor isoforms
Prostaglandins, are ubiquitously produced and act locally in an autocrine or
paracrine manner by binding to G-protein coupled receptors (Findlay et al., 1993; Hata
and Breyer, 2004). All eight prostanoid receptors identified to date (TP: tromboxane
receptor; DP; prostaglandin D receptor; EP: prostaglandin E receptor [EP1, EP2, EP3,
EP4]; IP: prostaglandin I receptor, and FP: prostaglandin F receptor) are integral
membrane proteins that possess seven transmembrane domains (α helices). These
receptors are coupled to specific G proteins mediating the formation of second
messengers such as cAMP, DAG and inositol trisphosphate (IP3; as reviewed by Tsuboi
and coworkers, (2002). The extracellular parts of the receptor can be glycosylated or
form disulfide bonds between highly conserved cysteine residues to stabilize the receptor.
The intracellular loops between α helices 5 and 6 and the C-terminal segment are
important for interactions with G proteins. The prostanoids receptors are classified
according to the prostanoid ligand that each binds with greatest affinity. Recently, a ninth
prostaglandin receptor, CRTH2, was identified on Th2 cells (Hirai et al., 2001).
Two differentially spliced variants of the sheep FP receptor have been reported,
the original FPr re-named FPA and a truncated form called FPB (Pierce et al., 1997).
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These variants exhibit similar ligand binding profiles and G protein coupling preferences
(Pierce et al., 1997). However, the C terminal tail of the FPA, but not the truncated FPB,
can be phosphorylated by PKC, leading to agonist-induced desensitization and
internalization (Fujino et al., 2000). In contrast, FPB does not undergo agonist-induced
internalization but instead experiences constitutive internalization (Srinivasan et al.,
2002). In addition, both isoforms are able to stimulate IP3 accumulation to the same
maximum, but the basal level of hydrolysis is 130% higher for the FPB than the original
FPA isoform (Pierce et al., 1997).
Another type of FP receptor isoform, FPa, has recently been cloned in bovine
(Ishii and Sakamoto, 2001). FPa is generated by alternative splicing at the middle of the
sixth transmembrane domain, resulting in the lack of a seven transmembrane domain and
an intercellular carboxyl tail. Transfected cells with FPa failed to stimulate PKC after
treatment with PGF2α; whereas, cotransfection of an excess amount of FPa markedly
reduces the original FP-mediated PKC response, suggesting that FPa could play a role as
a negative regulator to attenuate normal FPr function (Ishii and Sakamoto, 2001).
Recently, Sakamoto et al. (2002) identified the cDNA clones for five novel FPr
isoforms from a bovine corpus luteum cDNA library. The sequence analysis revealed that
these clones encoded the amino acid sequences of the original FPr (Sakamoto et al.,
1994) and the following clone-specific regions. Because only one copy of the FPr gene
has been identified in the bovine (Ezashi et al., 1997), these clones named FP-α, FP-β,
FP-γ, FP-δ, and FP-ε were identified as novel FPr isoforms generated by alternative
mRNA splicing. These proteins are constituted of 325, 326, 339, 293, and 298 amino
acids, respectively. These isoforms can be classified based in the location of the splicing
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site into two groups. FP-α, FP-β, FP-γ can be potentially spliced within the fourth
intracellular C-tail. These isoforms can be classified into the same group (Type I), which
is composed of the common overall sequences from the N-terminus through
transmembrane segment VII and the isoform-specific tail. The other isoforms, FP-δ and
FP-ε, are classified into the second group (Type II), which contains the variation from the
fourth extracellular domain through the C-tail. Hydrophobicity analysis revealed that
Type I isoforms possess intact seven transmembrane domains, while the Type II isoforms
carry truncated structures lacking transmembrane domain VII and the intracellular C-tail
(Sakamoto et al., 2002). In fact, the C-terminal region of the Type II isoforms may be
buried in the plasma membrane or protrude into the extracellular region and therefore
their ability to interact with G proteins and stimulate a cell signaling cascade would be
totally inhibited. As previously demonstrated by Ishii et al. (2001), these Type II isoforms
may function as suppressors for the normal activation of PKC after PGF2α binding to the
original FPr. The mRNA of these novel FPr isoforms and the original FPr isoforms were
shown to be expressed in the bovine corpus luteum at the same time during the estrous
cycle and pregnancy (Sakamoto et al., 2002). This suggests a cooperative role of these
isoforms with the original FP during the estrous cycle and pregnancy.

18. Prostaglandin F2α receptor agonists and antagonists
Development of potent and selective FP receptor agonists has resulted in the
ability to investigate specific cellular responses coupled to the activation of these
receptors (for example, activation of phospholipase C, increases in intracellular levels of
calcium and activation of PKC). Some of the FPr agonists include bimatoprost,
39

latanoprost and travoprost (Sharif et al., 2002). These substances possess similar
chemical structures and shapes as the endogenous ligand and therefore are able to bind to
the receptor and trigger a cellular response by “mimicking” the interaction of the
endogenous ligand to the receptor (Jasper and Insel, 1992). Agonists can be classified as
full or partial agonists (Jasper and Insel, 1992). A partial agonist binds to the specific
receptor, but does not cause as much of a physiological change as does a full agonist
(Franciosa, 1989). Moreover, a partial agonist can bind to a large number of receptors
and competitively inhibit action of a full agonist for the same receptor (Franciosa, 1989).
Antagonists for the FPr are being used to positively identify FPr mediating
functional responses in vitro or in vivo. Some FPr antagonists include AL-3138, AL8810, PGF2α dimethylamine, dimethylamide, glibenclamide and phloretin (Griffin et al.,
1999; Sharif et al., 2000). Antagonist substances bind to receptors and do not produce
any physiological responses. Antagonists are classified as competitive antagonists or noncompetitive antagonists. Competitive antagonists compete with the endogenous ligand/s
for the active site of the receptor. Once the antagonist is bound to the receptor, it does not
produce any physiological response in the cell and does not allow the endogenous ligand
to bind to the same receptor. Competitive antagonists produce a concentration dependent
shift in the endogenous ligand concentration-response curve, without decreasing the
agonist-induced maximal response. Another effect of a competitive antagonism is the
increase in the Kd of an agonist when increasing concentrations of the competitive
antagonist. An example of this is the effect of AL-8810 concentration on the
concentration-response curves of fluprostenol, a full agonist of the FP receptor (Sharif et
al., 2002). Griffin et al. (1999) characterized the pharmacological activities of AL8810 at
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the FP receptor. Authors concluded that previous exposure of mouse fibroblast to AL8810 abolished the production of IP3 associated to FPr stimulation by FPr agonist
(fluprostenol) or its endogenous ligand (PGF2α). In addition, AL-8810 did not have any
antagonistic activity at several other prostanoid receptors such as TP, DP, EP2 and EP4.
In agreement with these findings, several other studies indicated that AL-8810 inhibited
production of IP3 after activation of FPr (Sharif et al., 2002; Kelly et al., 2003; Sharif et
al., 2003; Sharif et al., 2003). During non-competitive antagonism, an antagonist binds to
its receptor on a different site from the endogenous ligand. In this case, binding of the
antagonist does not block the endogenous ligand binding (or vice versa), but the receptors
can not get activated when the antagonist is bound to it. The antagonist also lowers the
concentration of free ligand and has no effect on the Kd for the agonist.

19. Prostaglandin F2α association with early embryonic loss
The first indications that PGF2α were involved in embryonic loss occurred in a
series of experiments in the “short cycle” cow at West Virginia University. In the
postpartum cow, the first ovulation is followed by a short luteal phase (short cycle) due to
premature release of PGF2α (Cooper et al., 1991). Cows with short luteal phase failed to
maintain pregnancy even when exogenous progestogen was provided (Breuel et al.,
1993). Moreover, when good quality frozen-thawed embryos were transferred to
progestogen-supplemented animals on day 7 after estrus, pregnancy was maintained in
28% of short cycle cows compared to 58% of cows with normal luteal phase (Butcher et
al., 1992). However, pregnancy rates did not differ when day-6 embryos from short cycle
or normal cycling cows were transferred to normally cycling recipients (Schrick et al.,
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1993), suggesting that an improper uterine environment appears to play a role in lower
survival of embryos in cows with short cycle as compared to cows with normal luteal
phases. Schrick et al. (1993) observed that concentrations of PGF2α in flushing media
from cows with short luteal phases were more than double those from cows with normal
luteal phases (636 ± 82 and 288 ± 90 pg/ml, respectively). Furthermore, embryo quality
tended to be negatively correlated with concentrations of PGF2α in the flushing media (r
= -0.42; P=0.07). Thus, a direct negative effect of PGF2α may be implicated in lowering
embryonic survival as demonstrated in vitro in the mouse (Harper and Skarnes, 1972),
rabbit (Maurer and Beier, 1976), and rat (Breuel et al., 1993).
Effects of PGF2α on embryo survival have been examined in several studies using
progestogen-supplemented cows to replace the regressing corpus luteum. Buford et al.
(1996) demonstrated that PGF2α was detrimental to embryonic survival when 15 mg of
PGF2α every 8 h was injected to non-lactating cycling beef cows during days 4 through 7
or 5 through 8 after insemination, but pregnancy rates remained high when lutectomy
(removal of the corpus luteum) was performed before PGF2α treatment begun. Similarly,
PGF2α administration to progestogen-supplemented beef cows on days 5 to 8
postbreeding reduced pregnancy rates (23%) compared to control (72%), whereas
lutectomy prior to PGF2α administration tended to improve pregnancy rates (55%; Seals
et al., 1998). Removal of the corpus luteum eliminates oxytocin release from the corpus
luteum and blocks the positive feedback loop between oxytocin and PGF2α. As a result,
PGF2α concentration in the uterine lumen would remain low, allowing embryonic
development to occur. Furthermore, Seals et al. (1998) reported that detrimental action(s)
of PGF2α occurred during early embryonic development (days 5 to 8) since
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administration of PGF2α during filamentous embryo development (beyond day 10) had no
effect on maintenance of pregnancy.
Buford et al. (1996) demonstrated that postpartum cows bred at their first estrus
after weaning had higher pregnancy rates when lutectomy was used in conjunction with
flunixin meglumine (an inhibitor of COX-1 and COX-2), but lutectomy alone failed to
maintain pregnancy rates. The authors suggested that both premature secretion of PGF2α
and a factor released by the regressing corpus luteum may contribute to embryonic death
in the postpartum cow with a short luteal phase.
Oxytocin, which is released by large cells of the regressing corpus luteum in
response to PGF2α, can increase secretion of PGF2α from the uterus (Milvae and Hansel,
1980). Lemaster et al. (1999) treated progestogen-supplemented cows with oxytocin
rather than PGF2α in the same type of experiment performed by Seals et al. (1998).
Administration of oxytocin on days 5 through 8 every 8 h reduced pregnancy rates to
33% compared to the control group (80%). In the same study, administration of flunixin
meglumine blocked the negative effects of oxytocin, while lutectomy did not; thus, the
role of oxytocin on embryonic death may involve further release of PGF2α rather than
having a direct negative effect on the embryo.
Numerous factors such as heat stress (Putney et al., 1989; Malayer et al., 1990),
nutrition (Butler, 1998), mastitis (Hockett et al., 2000), manipulation of the reproductive
tract during embryo transfer and artificial insemination (Odensvik et al., 1993; Scenna et
al., 2005), and plant toxins (Woclawek-Potocka et al., 2005) may contribute to early
embryonic losses (before day 8) through premature release of uterine luminal
concentrations of PGF2α in cattle. Administration of flunixin meglumine or ibuprofen
43

lysinate (inhibitors of COX-1 and COX-2) at time of embryo transfer improved
pregnancy rates in cows (Elli et al., 2001; McNaughtan et al., 2002; Pugh et al., 2004;
Purcell et al., 2004; Scenna et al., 2005). Furthermore, low-dose aspirin treatment
improved implantation and pregnancy rates in human patients undergoing in vitro
fertilization and transfer (Rubinstein et al., 1999). Thus, in vivo and in vitro studies have
shown that PGF2α decreased embryonic development and survival in several species.

20. Embryo transfer
The objective of a multiple ovulation and embryo transfer (MOET) program in
livestock production is the rapid acquisition of superior genetics and to increase the
productive life of superior donor cows by increasing the number of its valuable progeny
through this technique (i.e. obtaining 20 transferable embryo per year resulting in 10
pregnancies instead of only having one calf per year when not using ET). Currently, the
ET technique is widely used around the world, with more than 500,000 embryos being
transfer annually (Thibier, 2000). Briefly, during any MOET program, the estrous cycle
of a donor cow is synchronized, the growth of follicles in each ovary is stimulated by
injecting follicle stimulating hormone (FSH), and the donor cow is observed for estrus
and artificially inseminated with frozen semen 12 and 24 h after heat detection (Seidel,
1981). Embryo recovery is performed seven days after estrus by placing a catheter
through the cervix and up to the upper third of each uterine horn or in the uterine body
(Drost et al., 1976). The uterus is flushed several times with phosphate buffered solution
(PBS) containing antibiotics and bovine serum albumin or a synthetic surfactant such as
polyvinyl alcohol (PVA) and the embryos are recovered in a filter. Next, embryos are
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searched under a microscope, loaded in holding medium into 0.25 mL straws and transfer
fresh to recipient cows or frozen in glycerol or ethylene glycol for future use.
The first successful ET in mammals was recorded in 1891 using rabbit embryos
(Heape, 1891). The next successful embryo transfer pregnancies resulted in rabbit
(Pincus, 1930) and rat (Nicholas, 1933). The first ET calf was born following the surgical
transfer of a slaughterhouse-derived 5-day old embryo (Willett et al., 1951). Commercial
ET in cattle started in the early 1970’s, primarily as a result of the high prices paid for
breeders for “exotic” beef cattle that had been imported in small numbers from Europe
(Betteridge, 2000). This technique was done by mid-ventral surgical exposure of the
uterus and ovaries with the donor under general anesthesia. Surgical ET was only
possible in “in-house” programs with suitable facilities and in beef cows due to the fact
that the udder of dairy cows hindered mid ventral access to the reproductive tract.
However, the introduction of non-surgical embryo recovery (flushing) in the mid-1970’s
(Elsden et al., 1976) and non-surgical embryo transfer in the late 1970’s (Bowen et al.,
1978) allowed ET to be practiced on the farm and in dairy animals. Prior to the early
1980’s, the inability to freeze and thaw bovine embryos made it necessary to synchronize
a sufficient number of recipient animals so that all recovered embryos could be
transferred fresh. Fortunately, development of freezing protocols utilizing dimethyl
sulfoxide or glycerol as cryoprotectants (Wilmut and Rowson, 1973) made ET more
appealing to producers and a much more efficient technologicalley.
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21. Efficiency and limitations of embryo transfer
Efficiency of embryo recovery is probably between 70 to 90% (Seidel, 1984) and
if no complications occur during uterine flushing (bleeding, clotting of the filter, cows
going down in the chute, etc.) the procedure takes no longer than 30 min per cow. When
performing ET, it is necessary to synchronize the estrous cycle of recipient cows with the
estrous cycle of donor cows (Rowson et al., 1972; Lawson et al., 1975; Hasler, 2001).
Asynchrony between donor and recipient estrous cycles greater that ± 24h resulted in
poor pregnancy rates following ET (Hasler et al., 1987; Hasler, 2001). Moreover, if
asynchrony between donor and recipient estrous cycles exists, then a synchrony between
embryo stage with the day of estrous cycle of recipient cows should be made (Wright,
1981; Lester and McNew, 1999). For example, morula stage embryos should be
transferred to recipients on day 6 ± 12h after estrous detection and blastocyst stage
embryos should be transferred to recipients on day 7 ± 12h after estrous detection. Today,
pregnancy rates in beef cattle after non-surgical embryo transfer of in vivo-derived
frozen-thawed (ethylene glycol) embryos is about 40 to 55% (Leibo, 1986; Malayer et al.,
1990; Nibart and Humblot, 1997; Lester and McNew, 1999), whereas pregnancy rate of
those transferred fresh is about 55% to 80% (Hasler, 2001).
The biggest problem in the embryo transfer industry is the variability in
superovulatory response of donor cows (Seidel, 1984). The average of transferable
embryos recovered per cow after a superovulatory treatment is in the range of 5 to 7
(Donaldson and Perry, 1983; Hasler et al., 1983). However, many donors yield no
transferable embryos or only a few, and in rare cases more than 30 transferable embryos
are recovered (Seidel, 1984). In addition, administration of the same dose of FSH to the
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same group of cows can result in cows not responding at all and presenting small
ovaries, cows responding accordingly to the expectations, and cows overstimulated with
very large ovaries and often yielding no transferable embryos (Seidel, 1981).
Superovulation can be performed every 60 days after allowing donor cows to have at
least two estrous cycles between superovulations (Hasler, 2003). Recently, Hasler (2003)
described a superovulation protocol called “donor quick turn around” that significantly
reduces this interval. The protocol consists of injecting a dose of PGF2α and the insertion
of a progesterone implant immediately after embryo recovery. Ten days later, the implant
is removed and superovulation initiated following the next estrus with an average of 40
days between superovulations. A disadvantage of superovulation programs is that the
donor response to this treatment sometimes decreases after repeated applications (Seidel,
1981; Donaldson and Perry, 1983). Several other factors influencing superovulatory
treatments and embryo transfer were recently investigated by Stroud and Hasler (2006).
In this review, the total number of ova/embryos recovered, the number of transferable
embryos, and pregnancy rates after embryo transfer, were all positively correlated to
good farm management (nutrition, recipient selection, synchronization protocols, estrous
detection, and synchrony between donor and recipient) and semen evaluation before
insemination of donor cows. Schrick et al. (2003) demonstrated a highly significant
relationship between semen quality and the percentage of fertilized ova and transferable
embryos in superovulated donors. Moreover, semen quality was also positively related to
the percentage of excellent-quality embryos.
Embryo mortality after natural mating or AI from day 24 to term is only between
3 and 5% (Paisley et al., 1978; Sreenan and Diskin, 1986). These losses are in agreement
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with data reported by King et al. (1985) who investigated losses associated to fresh
embryo transfers. In this study, 3.15% and 2.14% pregnancies resulted in abortion
between 2 and 3 months and 3 to 7 month of gestation, respectively. On the other hand,
pregnancy rates from day 60 to term after transfer of frozen-thawed embryos resulted in
abortion rates of 9.6 and 12.8% (Dochi et al., 1998). McMillan and Donnison (1999), in
an attempt to understand maternal contributions to fertility in recipient cows, transferred
in vitro-produced blastocyst stage embryo into contemporary beef heifers. After
pregnancy diagnosis, pregnancies were terminated with a luteolytic dose of PGF2α and
the process repeated 6 more times over a period of 26 months. Based on pregnancy data
obtained at 60 days following each round of transfers, heifers were ranked as high and
low fertility. Pregnancy rates for the High and Low sub-herds were 76% and 11%,
respectively, with 55% and 37% of this differences due to losses before day 25 (return to
estrous) and losses between day 25 and 35, respectively. Moreover, when other
reproductive parameters related to fertility were evaluated (site of ovulation, incidence of
standing estrus, interval to end of estrus to standing estrus, and progesterone profiles
during the estrous cycle), no differences between these two groups were observed,
indicating no differences in fertility at the level of the ovary. The authors suggested that
the mechanism of maternal recognition of pregnancy (MRP) is a major cause of
differences between these two groups; however, losses during MRP were not observed.
Dunne et al. (2000) reported that embryo loss following artificial insemination in beef
heifers occurred by day 14 after mating with little loss after this time.
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22. Implications of prostaglandin F2α release during embryo transfer in cows
The bovine endometrium contains relatively large amounts of arachidonic acid
that can be rapidly converted to different products such as PGF2α (Salamonsen and
Findlay, 1990). In fact, manipulation of the reproductive tract during embryo transfer
resulted in PGF2α release from the uterine endometrium (Scenna et al., 2005). Other
studies have also reported a release of PGF2α following uterine manipulation in mares
(Kask and Odensvik, 1995), sows (Kunavongkrit et al., 1984) and cows (Wann and
Randel, 1990). On the other hand, Odensvik et al. (1993) did not report an increase in
concentrations of plasma PGF2α after non-surgical embryo transfer in heifers. Differences
among these studies may be attributed to differences in breed, handling of blood samples,
and in the methodology used for determining PGF2α concentrations (indirect
determination of PGF2α through measuring PGFM vs. direct determination).
Manipulation of the reproductive tract causes uterine trauma followed by an
inflammatory process with release of several chemical mediators such as cytokines and
prostaglandins. One of the most important cytokines, tumor necrosis factor α (TNF-α), is
capable of inducing PGF2α release by luteal cells (Nothnick and Pate, 1990) and epithelial
cells in the uterine endometrium via activation of PLA2 and nitric oxide synthase
(Skarzynski et al., 2000). Moreover, Okuda et al. (2002) suggested that endometrial TNFα may be a trigger for the production of PGF2α from the uterine endometrium during
luteolysis. Since treatment of luteal cells with PGF2α induced further production of PGF2α
by this cell type in sheep (Rexroad and Guthrie, 1979; Wade and Lewis, 1996) and pigs
(Guthrie et al., 1979), PGF2α release after embryo transfer in cows may be able to
stimulate its own production from the reproductive tract.
49

Even though release of PGF2α during embryo transfer may not result in luteolysis,
embryonic survival may be compromised by the presence of small concentrations of
PGF2α in the uterine lumen, creating a “hostile environment” for embryonic development.
Scenna et al. (2004) demonstrated that development of in vitro-produced 16- to 32-cell
embryos to blastocyst stage was reduced by addition of PGF2α in the culture media. In
addition, culture of in vivo-derived compact morulae in medium containing PGF2α did not
affect development to blastocyst, but reduced hatching rates (Scenna et al., 2004). This is
in agreement with Maurer and Beier (1976) who reported that addition of PGF2α to
culture media directly decreased the ability of 8-cell rabbit embryos to form expanded
and hatched blastocysts, but had no effect on development to early blastocyst. Successful
hatching of the embryo is thought to be a key event for further embryonic development
and proper implantation in humans (Petersen et al., 2004). In fact, assisted hatching of
human embryos (consisting in creating a complete or partial hole in the zona pellucida)
has been shown to result in better implantation rate after embryo transfer in humans (Ali
et al., 2003; Kung et al., 2003; Wong et al., 2003).
Administration of flunixin meglumine (FM), an inhibitor of PGF2α synthesis, at
the time of embryo transfer resulted in increased pregnancy rates at the time of embryo
transfer (Scenna et al., 2005). The same study showed no differences on pregnancy rate
of quality 1 embryos following administration of FM when compared to control
recipients. However, transfer of quality 2 embryos to recipient animals receiving FM
resulted in higher pregnancy rates than control animals, indicating that developmentally
compromised embryos (quality 2) are most susceptible to deleterious effects of PGF2α
than those of better quality (quality 1).
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In agreement with these findings, Elli et al. (2001), McNaughtan et al. (2002),
Pugh et al. (2004) and Purcell et al. (2004) reported beneficial effects of prostaglandin
synthesis inhibitors on pregnancy rates in recipient cows after embryo transfer. In
humans, women undergoing in vitro fertilization and receiving a daily oral dose of aspirin
(an inhibitor of prostaglandin synthesis) had better ovarian responsiveness (greater
number of follicles and oocytes retrieved), uterine and ovarian blood flow velocity,
implantation, and pregnancy rates than women receiving placebo (Rubinstein et al.,
1999). Similarly, Waldenstrom et al. (2004) reported higher pregnancy rates in women
undergoing IVF and receiving a daily dose of aspirin from the day of embryo transfer
until pregnancy diagnosis when compared to women not receiving a treatment.
In conclusion, PGF2α synthesis and release at the time of embryo transfer may
result in reduced pregnancy rate of recipient cows by altering/inhibiting the normal
process of hatching. Moreover, developmentally-compromised embryos (those of lower
quality) may be more susceptible to the effects of PGF2α than good quality embryos. New
therapeutic techniques aimed at inhibiting synthesis or binding of PGF2α to its receptor in
bovine embryos will likely improve reproduction in cattle, as well as in humans
undergoing assisted reproduction programs.
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CHAPTER 3
RECEPTOR-MEDIATED EFFECTS OF PROSTAGLANDIN F2α ON
BOVINE EMBRYOS

1. Abstract
Prostaglandin F2α has been shown to have detrimental effects on embryonic
development, quality and hatching ability of embryos and pregnancy rates in cows. In
recipient cattle, administration of flunixin meglumine (a cyclooxygenase-1 and -2
inhibitor) at embryo transfer reduced detrimental effects associated with PGF2α actions on
establishment of pregnancy. Information regarding the presence of prostaglandin F2α
receptor (FPr) mRNA and protein in bovine embryos is absent in the literature. The
objectives of the current study were 1) to identify the period of time where in vitroderived embryos are most susceptible to PGF2α and 2) to determine the presence of
prostaglandin F2α receptor (FPr) mRNA and protein in bovine embryos. Results indicated
that culture of pre-compacted embryos for 48 h in medium containing 1 ng/mL of PGF2α
had decreased development to compact morula when compared to control embryos (PGF
1=55%C vs. CON=64%; P<0.05). On the other hand, culture of compacted embryos in
medium containing 1 ng/mL of PGF2α did not decrease development to blastocyst (PGF
1=57 vs. CON=59%). In addition, expression of FPr mRNA and protein in bovine
embryos was confirmed by real time PCR and Western Blot analysis, respectively. In
conclusion, PGF2α decreases embryonic development of bovine embryos to compact
morula, but once compaction occurred, PGF2α does not appear to affect further
52

embryonic development in vitro. Furthermore, PGF2α can have a direct negative effect on
development of bovine embryos by activating its own cell membrane receptor.

2. Introduction
Prostaglandins, also called prostanoids, are ubiquitously produced compounds
that mediate many physiological processes, including many reproductive functions
(reviewed by Weems and coworkers, (2006). Receptors for tromboxane A2 (TP),
prostaglandin D2 (DP), prostaglandin E2 (EP1-4), prostaglandin I2 (IP), and prostaglandin
F2α (FP), are integral membrane proteins that present seven transmembrane domains and
are coupled to specific G proteins mediating the formation of second messengers such as
cAMP, DAG and inositol triphosphate (Findlay et al., 1993; Hata and Breyer, 2004). The
prostaglandin F2α receptor (FPr) has been cloned from bovine (Sakamoto et al., 1994),
ovine (Graves et al., 1995), mice (Sugimoto et al., 1994), rat (Kitanaka et al., 1994) and
human (Abramovitz et al., 1994) cDNA libraries. In addition, several isoforms of this
receptor have been cloned from cDNA libraries of ovine and bovine corpus luteum
(Sakamoto et al., 1994; Pierce et al., 1997; Ishii and Sakamoto, 2001; Sakamoto et al.,
2002).
Embryonic losses in bovine appear to occur soon after the embryo enters the
uterus (5 to 8 days after mating or insemination), when the morula stage embryo is
transitioning to blastocyst (Ayalon, 1978; Maurer and Chenault, 1983; Wiebold, 1988;
Dunne et al., 2000). Previous studies have shown a detrimental effect of PGF2α on in
vitro development of rat, rabbit and bovine embryos (Maurer and Beier, 1976; Breuel et
al., 1993; Scenna et al., 2004). Furthermore, administration of PGF2α on days 5 through 8
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after artificial insemination or mating has also been shown to decrease embryonic
development, quality and pregnancy rates in progesterone-supplemented cows (Buford et
al., 1996; Hockett et al., 2004; Sales et al., 2004). In addition, administration of
prostaglandin synthesis inhibitors increased pregnancy rates after transfer in cows (Elli et
al., 2001; McNaughtan et al., 2002; Pugh et al., 2004; Purcell et al., 2004; Scenna et al.,
2005).
The objectives of this study were 1) to identify the period of time during in vitro
embryo development that embryos are most susceptible to detrimental effects of PGF2α,
and 2) to determine the presence of FPr gene and protein expression in bovine embryos.

3. Experimental procedures
3.1 Materials
Polyvinyl alcohol (PVA), bovine serum albumin (BSA), percoll, penicillamine,
hypotaurine, epinephrine and the majority of reagents used for in vitro production of
bovine embryos were purchased from Sigma Chemical, Inc. (St. Louis, MO).

Tissue

culture medium-199, gentamicin, and penicillin-streptomycin were purchased from
Specialty Media, Inc. (Phillipsburg, NJ). Fetal bovine serum (FBS) was obtained from
BioWhittaker (Walkersville, MD). Folltropin-V and Vigro holding Plus were purchased
from Bioniche Life Sciences, Inc. (Belleville, ON). Ovaries were purchased from a local
abattoir. Media (HEPES-TALP, IVF-TALP, AND SPERM-TALP (Parrish et al., 1988))
and KSOM (Edwards et al., 2005), were prepared in the laboratory. Sperm characteristics
(percent motile sperm and concentration) were analyzed using a computerized sperm
analyzer (CASA; Hamilton Thorne Biosciences; Beverly, MA). The PicoPure RNA
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isolation Kit was purchased from Arcturus (Mountain View, CA). DNase I enzyme and
RNAlater were purchased from Ambion (Austin, TX). Trizol Reagent was obtained from
Invitrogen (Carlsbad, CA). All reagents for the RT reaction (5X RT Buffer, 25 mM
Magnesium Chloride, Random Primers, RNasin Ribonuclease Inhibitor, dNTP Mix, and
M-MLV Reverse Transcriptase) were purchased from Promega (Madison, WI). iQTM
SYBR Green Supermix was purchased from Bio-Rad (Hercules, CA).

3.2. General procedures for in vitro production of bovine embryos
The procedures utilized for in vitro production of embryos (IVP) were
modifications of procedures previously described by Lawrence et al. (2004). Ovaries
obtained from an abattoir were packaged in thermoses and contained within a cooler
during air transport to the laboratory. Upon arrival to the laboratory, ovaries were
immediately washed with warm tap water equilibrated to arrival temperature of ovaries
(generally between 28 to 30°C). Excess tissue surrounding ovaries was removed with
scissors and ovaries were washed with warm tap water an additional time.
For oocyte recovery, ovaries were held firmly by clamping the base of the ovary
with a hemostat and checkerboard incisions were made across follicles (approximately 38 mm in diameter) using a scalpel blade. Ovaries were vigorously washed in oocyte
collection medium (OCM) in order to remove cumulus oocyte complexes (COCs)
contained within the follicles. Collection medium was filtered and rinsed using an Emcon
Filter unit (Vet Concepts, Spring Valley, WI) until medium was clear. Medium
containing COCs was poured into a gridded culture dish where searching of oocytes was
accomplished. Cumulus oocyte complexes were transferred to an “X” plate containing
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OCM and washed four times to eliminate cellular debris. Cumulus oocyte complexes of
good quality (even cytoplasm, at least 3-4 layers of tight cumulus cells) were washed in
oocyte maturation medium (OMM; M-199 with Earle’s salts, 10% fetal bovine serum, 50
μg/mL gentamicin, 5 μg/mL LH, 0.2 mM sodium pyruvate, and 2 mM L-glutamine) and
placed in groups of approximately 50 COCs per well in a 4-well plate containing 500 μL
OMM. Maturation of oocytes was performed in an incubator at 5.5% CO2 in air at 38.5°C
until time of fertilization (approximately 24 h after placement in OMM). Maturation
medium was equilibrated in the incubator (5.5% CO2 in air at 38.5°C) the day before
oocyte collection.

3.2.1. Sperm preparation and in vitro fertilization
After oocyte maturation (22-24 h in OMM in an incubator at 5.5% CO2 in air at
38.5°C),

OMM

from

each

well

was

carefully

removed

and

25

μL

of

penicillamine/hypotaurine/epinephrine (PHE) and 500 μL of fertilization medium (IVFTALP) were added to each well. Two straws of semen from two bulls (140 Se5, 140
Se55, 30 SM002, CG30, SM 101), known to have high motility as well as producing high
cleavage and blastocyst percentages were used to fertilize oocytes for every replicate of
the study. Briefly, semen straws were removed from liquid nitrogen tank and placed in
water at 36.7°C for 45 sec. Each straw was then emptied on top of a discontinuous
percoll density gradient (3 mL 45% percoll over 3 mL 90% percoll contained in a 15 mL
conical tube) and sperm was centrifuged at 760 x g for 15 min in order to remove excess
extender, debris, and nonmotile sperm prior to fertilization. Sperm pellet present at the
bottom of the 90% fraction was collected and transferred to 10 mL SPERM-TALP and
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centrifuged at 200 x g for 8 min. Supernatant was removed and sperm pellet re-suspended
in 100 μL of modified IVF-TALP. Sperm concentration and motility were determined
using a CASA and sperm was added to each well at a final concentration of 500,000
motile sperm per well. Lastly, oocytes and sperm were incubated at 5.5% CO2 in air at
38.5°C for 18-22 h.

3.2.2. In vitro culture
Approximately 18-22 h post fertilization, putative zygotes (PZ) were denuded of
cumulus cells by vortexing. Putative zygotes were transferred to a 2 mL centrifuge tube
containing 50 μL of HEPES-TALP and vortexed for 5 min. Recovered putative zygotes
were washed 4 times in HEPES-TALP before transferring groups of approximately 40-50
zygotes to each well of a 4-well plate containing 500 μL of KSOM culture medium per
well. Zygotes were placed in a humidified atmosphere of 5.5% CO2, 7% O2, and 87.5%
N2 at 38.5°C until they were collected at 16-32 cells (approximately 97 h post IVF),
compact morula (approximately 145 h post IVF) or blastocyst stage (approximately 193 h
post IVF) to perform each experiment.

3.3. Time-specific effects of PGF2α during in vitro embryo development
Previous data in our laboratory have shown that addition of PGF2α to the culture
medium of pre-compacted in vitro produced embryos (during days 4 to 9 of embryonic
development) results in decreased embryonic development when compared to embryos
cultured in control medium (Scenna et al., 2004). In order to investigate time-specific
effects of PGF2α during in vitro embryo development, embryonic development of pre57

compacted (Experiment 1) and compacted embryos (Experiment 2) cultured in medium
containing PGF2α was compared to embryos cultured in control medium.

3.3.1. Preparation of PGF2α stock and treatment wells
Prior to the beginning of each experiment, prostaglandin F2α (1 mg; Cayman
Chemical Inc., Ann Arbor, MI, catalog#) was solubilized in 10 mL of DMSO (Stock #1
100,000 ng/mL). Then, 30 μL aliquots were stored at -20C° until needed. For each
replicate of the experiment, serial 10-fold dilutions of PGF2α stock #1 in KSOM-PVA
(0.3%) were made to yield 1 ng/mL of PGF2α in KSOM-PVA culture medium. Control
experimental wells were prepared by adding a DMSO (0.001%) concentration equal to
the one use to prepare 1 ng/mL of PGF2α in KSOM-PVA. Four-well plates containing
treatment wells (500 μl KSOM-PVA without the addition of PGF2α or with the addition
of 1 ng/mL PGF2α) were equilibrated in an incubator (5.5% CO2, 7% O2, and 87.5% N2 at
38.5°C) for at least 12 h before placing embryos in their respective treatments. Addition
of 1 ng/mL PGF2α has been previously shown to result in lowered embryonic
development of in vitro produced bovine embryos (Scenna et al., 2004).

3.3.2. Experiment 1: Effects of PGF2α on pre-compacted embryos
Procedures for oocyte collection, maturation, fertilization and embryo culture
were previously described under general methods. Pre-compacted (16- to 32-cell stage;
approximately at 97 h post IVF) embryos were rapidly transferred from KSOM culture
medium to pre-warmed HEPES-TALP for evaluation. Embryos were evaluated for
quality (normal shape, defined blastomeres, extruded blastomeres, cytoplasmic
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fragmentation, even cytoplasm) and evenly sorted according to their quality. Embryos
were rapidly washed at least twice in KSOM-PVA and transferred to their respective
treatments in a 4-well plate. Experimental plates were placed in the incubator (5.5% CO2,
7% O2, and 87.5% N2 at 38.5°C) for 2 additional days when embryo development to
compact morula stage was determined using IETS guidelines for classification of bovine
embryos (Stringfellow and Seidel, 1998). Data for development to compact morula were
analyzed using a randomized block design model with replicate (a 4 well plate with each
well containing a treatment and a group of embryos considered an experimental unit) as
random effect and treatment as fixed effect performing mixed procedures of SAS
software (SAS 9.1, SAS Institute Inc., Cary, NC).
A total of 6 replicates were utilized to investigate the effects of PGF2α on pre
compacted in vitro-derived embryos. In each of these replicates, pre-compacted embryos
received one of the following treatments: 1) CON (KSOM-PVA; n= 183), or 2) PGF 1 (1
ng/ml PGF2α in KSOM-PVA; n= 184).

3.3.3. Experiment 2: Effects of PGF2α on compacted embryos
Procedures for oocyte collection, maturation, fertilization and embryo culture
were previously described under general methods. Compact morula stage embryos
(collected at approximately 145 h post IVF) were rapidly transferred from KSOM culture
medium to pre-warmed HEPES-TALP for evaluation. Embryos were evaluated for
quality (normal shape, defined blastomeres, extruded blastomeres, cytoplasmic
fragmentation, even cytoplasm) and evenly sorted according to their quality. Embryos
were rapidly washed at least twice in KSOM-PVA and transferred to their respective
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treatments in a 4-well plate. Experimental plates were placed in the incubator (5.5% CO2,
7% O2, and 87.5% N2 at 38.5°C) for 2 additional days when embryo development to
blastocyst stage was determined using IETS guidelines for classification of bovine
embryos (Stringfellow and Seidel, 1998). Data for development to blastocyst were
analyzed using a randomized block design model with replicate (a 4-well plate with each
of its wells containing one treatment; a group of embryos in each well was considered an
experimental unit) as random effect and treatment as fixed effect performing mixed
procedures of SAS software (SAS 9.1, SAS Institute Inc., Cary, NC).
A total of 11 replicates were utilized to investigate the effects of PGF2α on
compacted in vitro-derived embryos. In each of these replicates, compact morula stage
embryos received one of the following treatments: 1) CON (KSOM-PVA; n= 268), or 2)
PGF 1 (1 ng/ml PGF2α in KSOM-PVA; n= 278).

3.4. Determination of FPr mRNA and protein in bovine embryos
3.4.1. Preparation of embryo and semen samples for reverse transcription-real time-PCR
Due to a concern regarding the amplification of PGF2α transcripts associated with
the accessory sperm present in the zona pellucida (ZP) of bovine embryo (Nadir et al.,
1993), PCR was performed in ZP-intact and ZP-free in vitro-derived compact morula and
blastocyst stage embryos. Mechanical removal of ZPs from embryos was the preferred
method over pronase treatment because it also allowed PCR analysis of isolated ZPs.
Mechanical removal of ZPs was performed following procedures described by Edwards
et al. (2003) to remove ZPs of bovine embryos. Briefly, embryos were removed from
culture medium and washed 3 times in HEPES-TALP-PVA (0.3% PVA). Groups of 5
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embryos were transferred to 10 μL drops of 0.3M sucrose (Van Soom et al., 1996)
covered in mineral oil to induce shrinkage of the embryo mass. Following shrinkage of
embryos, the majority of the 0.3 M sucrose solution was removed, and as a result, the
weight of the mineral oil maintained embryos in place forming a tight group of embryos.
Next, a 27-gauge tuberculin needle associated with its corresponding syringe was used to
produce a hole in the ZP of each embryo. Each group of embryos was resuspended in
HEPES-TALP-PVA and transferred to HEPES-TALP-PVA in a 4-well plate. Using a
glass pipette just slightly thinner than the embryo’s size each embryo was liberated from
the ZP by gently pipetting. Zona pellucida-intact, ZP-free embryos and their
corresponding ZPs (in groups of 20-30 embryos or ZPs) were washed in HEPES-TALPPVA loaded in 2.5 μL of HEPES-TALP-PVA, lysed in 25 μL of RNA lysis buffer
(Arcturus, Mountain View, CA) and stored at -80°C until use.
Semen straws from the same bull (BN 354) utilized for in vitro production of
embryos used for detection of FPr protein were removed from liquid nitrogen tank and
placed in water at 36.7°C for 45 sec. Straw were then emptied on top of a discontinuous
percoll density gradient (3 mL 45% percoll over 3 mL 90% percoll contained in a 15 mL
conical tube) and sperm centrifuged at 760 x g for 15 min. Sperm pellet present at the
bottom of the 90% fraction was transferred to 10 mL HEPES-TALP-PVA column and
centrifuged at 200 x g for 8 min. Supernatant was removed and sperm pellet re-suspended
in 100 μL of modified IVF-TALP for determination of sperm motility and concentration.
Approximately 2,500,500 sperm were then lysed in 50 µL of RNA lysis buffer and stored
at -80°C until use.
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3.4.2. Isolation of RNA
Total RNA was isolated using the PicoPure RNA isolation Kit (Arcturus,
Mountain View, CA) as per the manufacturer’s instructions. Briefly, RNA was mixed
with 70% ethanol by gently pipetting and the mixture was added to an RNA purification
column. DNAse treatment was performed by addition and incubation of DNase I enzyme
(Qiagen, Valencia, CA) 15 min at room temperature in the RNA purification columns.
Several washes of the columns were performed previous to elution of RNA from the
column by using 12 μL elution buffer.
As a positive control, total RNA from bovine tongue epithelium was isolated
using Trizol Reagent (Invitrogen, Carlsbad, CA). Bovine tongue tissue was obtained from
a fresh tongue in a local abattoir. Epithelial cells were obtained by slicing of bovine
tongue epithelium in sections less than 0.5 mm thick. Collected tissue was immediately
placed in RNA later (Qiagen, Valencia, CA). Tissue was left at 4°C overnight and kept at
-80°C until use. To isolate RNA, 100 mg of tongue epithelium was placed in a 17 x 100
mm polypropylene tube containing 1 mL of Trizol and homogenized with a Tekmar
Tissumizer (Tekmar Co., Cincinnati, OH). Homogenized samples were incubated for 5
min at room temperature and then mixed with 0.2 mL of chloroform. Tubes were
vigorously shaken by hand for 15 sec and incubated at room temperature for 15 min.
Samples were centrifuged at 12,000 x g for 10 min at 4°C. Next, the aqueous phase was
transferred to a new tube, and in which RNA was precipitated by the addition of 0.5 mL
isopropyl alcohol and incubation of the samples at room temperature for 15 min. Samples
were centrifuged at 12,000 x g for 10 min at 4°C, the supernatant removed and the
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resulting RNA pellet washed once using 75% ethanol. Lastly, the RNA pellet was airdried for 5 min, dissolved in 50 μL of nuclease free water and stored at -80°C until used.

3.4.3. Reverse transcription
Isolated RNA from bovine embryos and bovine tongue epithelium was DNAase
treated and reversed transcribed into complementary DNA in a total volume of 20 μL.
The reaction mixture consisted of 1X RT buffer, 5 mM MgCl2, 1 mM of each dNTP, 0.25
nM random primers, 20 IU RNase inhibitor, and 100 IU moleney murine leukemia virus
reverse transcriptase (MMLV-RT). The RT reaction was carried out at 25°C for 10 min,
42°C for 1 h followed by a denaturation step at 99°C for 5 min and flash cooling to 4°C.
Controls for genomic DNA contamination were prepared by omitting reverse
transcriptase enzyme in the RT reaction.

3.4.4. Real time PCR
Polymerase chain reaction was performed using the iCycler iQTM Real-Time PCR
detection system (Bio-Rad, Hercules, CA) and the iQTM SYBR Green Supermix (BioRad, Hercules, CA). The PCR reaction mixture consisted of 25 μL 1X iQ Supermix (100
mM KCl, 40 mM Tris-HCl pH 8.4, 0.4 mM of each dNTP, iTaq DNA Polymerase 50
units/ml, 6 mM MgCl2, SYBR Green I, 20 nM fluorescein, and stabilizers), 1 μM
concentration of forward and reverse primers for FPr and β-actin (Table 1), nuclease free
water, and cDNA template from each RT reaction. Negative control for each primer set
consisted of PCR reaction mixture without the inclusion of cDNA (no template).
Amplification of housekeeping gene actin (Rambeaud et al., 2006), were used as standard
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Table 1. Details of primers used for RT-RT-PCR.

Gene

GenBank
Accesion
Number

Sense

Sequence

Location

Fragment
Size (bp)

PGF2α
receptor

NM181025

Forward
Reverse

5’-gcagaccaagcacagtgaaa-3’
5’-ctgacagccaaccacgtatg-3’

1487-1506
1618-1637

151

β-Actin AY141970.1

Forward
Reverse

5’-cggcattcacgaaactacct -3’
5’-gggcagtgatctctttctg-3’

855-875
978-997

143
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positive controls for the PCR reaction. The Real Time PCR protocol included an initial
step of 95°C for 15 min, followed by 40 cycles of 95°C for 15 sec, 55°C for 30 sec, and
72°C for 30 sec. Fluorescence data was acquired during the elongation step. Since the
melting curve of PCR products is sequence specific, it is used to identify PCR products.
Melting protocol was performed by holding temperature at 45°C for 60 sec and then
heating from 45 to 94°C, holding at each temperature for 5 sec while monitoring
fluorescence. Product identity was also confirmed by ethidium-bromide-stained 2%
agarose gel electrophoresis in 1X TBE (90 mM Tris, 90 mM borate, 2 mM EDTA, pH
8.3) visualized using a gel doc apparatus (Bio-Rad, Hercules, CA) and by target
sequencing (University of Tennessee Molecular Biology Core Facility). At least three
replicates containing ZP-intact and ZP-free embryos were utilized in this experiment.

3.4.5. Tissue collection for Western blot
In vitro-derived embryos were sorted according to their developmental stage in
compact morulae and blastocysts, whereas in vivo-derived (ethylene glycol or glycerol
frozen-thawed embryos) embryos at compact morula and blastocyst stage were pooled
together into one group. To avoid foreign protein contamination, embryos were washed at
least 3 times in HEPES-TALP supplemented with 0.3% PVA instead of BSA. Embryos
were lysed in 2% SDS Extraction Buffer as described by Morgan et al. (1993) with the
addition of a protease inhibitor cocktail (Roche, Indianapolis, IN). Lysate was heated at
94°C for 3 min and sonicated for 1 min. Lastly, samples were stored at -80°C until use.
Tissue from corpus luteum (CL) was removed from ovaries obtained at a local
abattoir. Tissue was cut in thin slices (less than 1 mm) with a scalpel blade and placed in
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a 17x100 mm polypropylene tube (BD Biosciences, San Jose, CA). Extraction buffer
with protease inhibitors was added to the tube and tissue homogenized in Tekmar’s
Tissumizer for approximately for 5 min or until no gross debris were observed.
Homogenate was centrifuged through a BD Falcon cell strainer (BD Biosciences
Discovery Labware, Bedford, MA) attached to a 50 mL conicle tube for 2 min at 700 x g,
aliquoted and stored at -80°C until use.
Two straws of frozen-thawed semen from two bulls (same bulls used for in vitro
production of embryos) were centrifuged at 760 x g for 15 min using a percoll density
gradient (3 mL 45% percoll over 3 mL 90% percoll contained in a 15 mL conical tube).
Sperm pellet at the bottom of the tube was transferred to 10 mL HEPES-TALP-PVA
(0.3%) and centrifuged at 200 x g for 8 min. Supernatant was removed and sperm pellet
re-suspended in 100 μL of HEPES-TALP-PVA (0.3%). A total of 100 μL from the sperm
mixture was combined with 100 μL of extraction buffer, heated at 94°C for 5 min and
stored at -80°C until use.

3.4.6. Western blot
Protein concentration from corpus luteum and embryos was determined using the
NanoOrange Protein Quantitation Kit following the manufacturer’s instructions
(Invitrogen, Carlsbad, CA) in a TBS-380 minifluorometer (Turner Biosystems,
Sunnyvale, CA). Proteins in each sample were loaded and electrophoresed on a 12% SDS
polyacrylamide gel using 1X SDS-Running Buffer (3.02 g Tris, 18.8 g Glycine, 10 ml
10% SDS, Qs to 1 lt) at 20 mAmp/100 V for 2.5 h. Electrophoresed proteins were
electroblotted onto a PVDF membrane (Bio-Rad, Hercules, CA)
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using a semi dry

apparatus (Bio-Rad, Hercules, CA) at 12 constant volts for 25 min. Prestained SDS
standards (Bio-Rad, Hercules, CA) and chemiluminescence standards (MagicMark XP
Standards, Invitrogen, Carlsbad, CA) were loaded to confirm transfer to PVDF
membrane and to serve as molecular weight standards when developing the western blot,
respectively. As positive control, a crude protein extract from bovine corpus luteum was
used to determine the presence of FPr protein. After electrotransfer, SDS gels were
stained with 0.1% Coomassie Blue solution to evaluate protein transfer efficiency,
whereas PVDF membranes were dried overnight at 4°C. Membranes were then rehydrated in 100% methanol for a few seconds, washed twice in water and blotted.
Proteins were blocked for 1 h at room temperature with 10% non-fat dried milk (NFDM)
in PBS. Blots were washed 3 times at 10 min intervals in PBS with 0.05% Tween-20
(PBS-T). Blots were incubated with primary antibody (rabbit polyclonal IgG raised
against mouse FP receptor, Cayman Chemical Inc, Ann Arbor, MI) for 1 h at room
temperature at a dilution of 1:1000 in 2% NFDM in PBS and washed 3 times with PBST. Blots were then incubated with secondary antibody (Goat anti-rabbit IgG, Pierce,
Rockford, IL) for 1 h at room temperature at a dilution of 1:1000 in 1% NFDM in PBS
and washed 3 times with PBS-T. Blots were developed using a chemiluminescence kit
(SuperSignal West Femto Maximum Sensitivity Substrate, Pierce, Rockford, IL)
following manufacturer’s instructions. In this study, at least 3 replicates of in vitroderived morulae, 3 replicates of in vitro-derived blastocysts, and 2 replicates of in vivoderived embryos were utilized to study FPr protein expression in bovine embryos.
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4. Results
4.1. Time-specific effects of PGF2α during in vitro embryo development
Incubation of pre-compacted embryos with 1 ng/ml of PGF2α in the culture
medium decreased the percentage of embryos reaching compaction 48 h later (PGF 1=55
± 7.7 vs. CON=64 ± 7.7%; P<0.05; Figure 2). Whereas, culture of compacted embryos in
medium containing 1 ng/ml of PGF2α did not result in lowered blastocyst formation (PGF
1=57 ± 7.3% vs. CON=59 ± 7.3%; P>0.05; Figure 2).

4.2. FPr gene
Prostaglandin F2α receptor transcripts were successfully amplified from ZP-intact
and ZP-free compact morula and blastocyst stage bovine embryos (Figure 3 and 4), as
well as from tongue epithelium (the positive control; Figure 4) and bovine sperm (Figure
4). In contrast, transcripts for FPr were not observed in mechanically removed ZPs. In
addition, amplification of the housekeeping gene β-actin was observed in all samples
including mechanically removed ZPs. DNA contamination was not evident as negative
controls did not result in any of the genes used being amplified (no template and RT
negative reactions; Figure 3 and 4). Amplification products were positively identified by
melting curve profiles and ethidium-bromide gel electrophoresis (Figure 3 and 4).

4.3. FPr protein expression
Because gene expression does not always correlate with protein expression,
western blots were performed on in vitro and in vivo-derived embryos. Western blot
analysis confirmed the expression of FPr protein in in vitro-derived blastocysts stage
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Figure 2. Embryonic development of pre-compacted (Experiment 1) and compacted
(Experiment 2) embryos after 48 h culture in medium containing 1 ng/ml of
prostaglandin F2α or in control medium. Embryonic development of pre-compacted, but
not compacted embryos was inhibited by addition of prostaglandin F2α to the culture
medium. a.bValues differ within treatments (P<0.05). Pooled standard errors were ± 7.7.
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A

β-actin ZP-Free Compact Morula
β-actin ZP-Free Blastocysts

FPr ZP-Free Compact Morula
FPr ZP-Free Blastocysts

B

β-actin

FPr

Figure 3. Real time RT PCR using SYBR Green I. A) Amplification curves for
prostaglandin F2α receptor (FPr) and β-actin transcripts in ZP-free and ZP-intact
blastocysts and ZP-free compact morulae. Each embryo sample was used for
amplification of FPr and β-actin transcripts; therefore each line represents an embryo
sample. Controls for genomic DNA contamination for each of these embryo samples
(omission of reverse transcriptase enzyme) showed no FPr amplification. B)
Amplification products were positively identified by melting curve profile. Three
replicates for ZP-intact and 3 replicates for ZP-free embryos at compact morula or
blastocyst stage were utilized for determination of FPr transcripts in in vitro-derived
embryos.
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Figure 4. Ethidium bromide gel electrophoresis: Lane 1: PCR markers; lane 2: FPr in
tongue epithelium (positive control); lane 3: FPr no template (negative control); lane 4: βactin in tongue epithelium; lane 5: β-actin no template (negative control); lane 6: FPr in
ZP-free blastocysts; lane 7: β-actin in ZP-free blastocysts; lane 8: FPr with RT negative
reaction ZP-free blastocyst; lane 9: FPr in ZP-intact blastocyst; lane 10: β-actin in ZPintact blastocyst; lane 11: FPr with RT negative reaction from ZP-intact blastocyst; lane
12: FPr in ZP-free compact morulae; lane 13: β-actin in ZP-free compact morulae; lane
14: FPr in RT negative from ZP-free compact morulae; lane 15: FPr in mechanically
isolated zona pellucidas; lane 16: β-actin in mechanically isolated zona pellucidas; lane
17: FPr in RT negative from mechanically isolated zona pellucidas.
71

embryos, in vivo-derived (compact morulae and blastocysts) embryos, sperm, and corpus
luteum samples (Figure 5). In addition, FPr was identified as approximately a 64 kDa
protein. Pre-absorption of the primary antibody with its corresponding blocking peptide
resulted in negative western blots which confirmed the specificity of the primary
antibody to the FPr. Detection of FPr in in vitro-derived compact morulae was not
evident.

5. Discussion
Several studies have indicated a negative effect of PGF2α on embryonic
development, hatching ability and embryo quality in different species (Maurer and
Chenault, 1983; Breuel et al., 1993; Buford et al., 1996; Lemaster et al., 1999; Hockett et
al., 2004). Moreover, Scenna et al., (2004) indicated that culture of pre-compacted in
vitro-derived bovine embryos in medium containing PGF2α decreased development to
blastocyst. In the later study, time specific effects of PGF2α on pre-compacted or
compacted in vitro-derived embryos could not be determined because pre-compacted
embryos were treated with PGF2α until assessment of development to blastocyst. The
objective of our initial experiment was to identify the period of time where in vitroderived embryos are most susceptible to detrimental effects of PGF2α. In this study,
addition of PGF2α to the culture medium of pre-compacted bovine embryos reduced the
ability of the embryos to undergo compaction. To the contrary, addition of PGF2α to the
culture medium of compacted embryos did not cause a reduction in blastocyst formation.
In a second experiment, the hypothesis that PGF2α has a direct negative effect on
embryos was strengthened by identification of FPr mRNA in ZP-free compact morula
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Figure 5. Western blot for FPr protein in bovine sperm, bovine corpus luteum (CL), zona
pellucida (ZP) intact in vivo-derived bovine embryos, and zona pellucida (ZP) intact in
vitro-derived bovine embryos.
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and blastocyst stage embryos. Mechanical removal of the embryo from the zona pellucida
was performed to avoid PCR amplification of PGF2α transcripts associated with accessory
sperm present in the zona pellucida (ZP) of the embryo (Nadir et al., 1993). In addition,
Western blot analysis indicated that in vitro-derived blastocysts and in vivo-derived
(compact morulae and blastocysts) bovine embryos, semen samples, and corpus luteum
(used as positive control) expressed FPr protein.
It is important to mention that amplification of FPr and β-actin transcripts were
observed in bovine sperm samples. Furthermore, β-actin transcripts, but not FPr
transcripts were amplified from mechanically isolated ZPs. These results suggest that
amplification of β-actin transcripts from ZPs are a consequence of amplification of
transcripts from accessory sperm present in the ZPs of in vitro-derived embryos. Lack of
FPr mRNA from ZP samples may be explained by a lower amount of FPr transcripts
compared to β-actin transcripts (a housekeeping gene) in the accessory sperm associated
with ZP. The presence of mRNA in sperm was also correlated with the presence of FPr
protein by Western blot.
Prostaglandin F2α receptor protein expression in in vitro-derived compact morulae
was not detectable; therefore, FPr gene expression did not correlate with its protein
expression in in vitro-derived compact morulae. The fact that we did not detect FPr
protein expression in compact morulae does not rule out the possibility that precompacted and compacted embryos express small amounts of FPr that under our
experimental conditions were unable to be detected, but were sufficient enough to cause
an effect of PGF2α on the embryo. In addition, due to the lipophilic characteristics of
prostaglandins (Bito, 1975) and the presence of prostaglandin transporters mediating
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influx and efflux of prostaglandins to cells (Lu et al., 1996; Chan et al., 1998), negative
effects of PGF2α in pre-compacted embryos may also occur via none receptor-mediated
events. This hypothesis agrees with a study performed by Scenna et al. (2004) in which
culture of pre-compacted bovine embryos in medium containing 1, 10 or 100 ng/ml of
PGF2α decreased development to blastocyst; however, 1 ng/mL of PGF2α had a more
detrimental effect than addition of 10 ng/mL (Scenna et al., 2004), suggesting that effects
of PGF2α did not involve a receptor-mediated event. Therefore, non receptor-mediated
effects of PGF2α on the embryo may explain in part the negative effects of PGF2α on in
vitro development of pre-compacted embryos observed in our initial experiment.
Moreover, lack of PGF2α effects on development of compact morulae to
blastocyst stage suggests that once the embryo compacts, PGF2α effects on the embryo
ceases. However, due to the fact that previous studies have indicated a reduction on
hatching rates of compacted bovine embryos with PGF2α (Scenna et al., 2004) and that
only a very low number of in vitro-derived embryos usually hatch from the zona
pellucida, negative effects of PGF2α on hatching may still be possible.
Until now, two isoforms for the FPr protein have been identified in ruminants; the
original FP isoform named FPA and a newer isoform generated by alternative mRNA
splicing named FPB (Pierce et al., 1997; Iwamoto et al., 1999). The molecular weight of
FPr protein presented in this study was approximately 64 kDA, which agrees with several
other studies showing expression of a 64 kDA FPr protein in bovine ocular tissues
(Ansari et al., 2004; Kaddour-Djebbar et al., 2005; Thieme et al., 2006). However, the
FPr molecular weight reported in our study differs from other studies in humans
(Abramovitz et al., 1994) and bovines (Sakamoto et al., 1995) after cloning of FPr in
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those species. The aforementioned studies estimated a molecular weight of 40,060 and
40,983 Daltons for the human and bovine FPr, respectively. In agreement with these
authors, Al-Matubsi et al. (2001) demonstrated the presence of a 43 kDa FPr in rat
myometrium by Western blotting.
In conclusion, our results indicated that direct effects of PGF2α on in vitro-derived
embryos occur before or during compaction, but the possibility of PGF2α affecting
hatching of blastocyst from the zona pellucida still remains. In addition, to our
knowledge, we have demonstrated for the first time the existence of FPr mRNA (in in
vitro-derived compact morulae and blastocyst) and protein (in in vitro-derived blastocysts
and in vivo-derived pools of morulae and blastocysts) in bovine embryos. These findings
suggest that PGF2α can have a direct negative effect on development of bovine embryos
by receptor and non receptor-mediated events.
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CHAPTER 4
DETRIMENTAL EFFECTS OF PROSTAGLANDIN F2α ON IN
VITRO EMBRYO DEVELOPMENT IN BOVINE ARE INHIBITED
BY A RECEPTOR ANTAGONIST

1. Abstract
Numerous studies have demonstrated negative effects of prostaglandin F2α
(PGF2α) on bovine reproduction. Moreover, previous data from our laboratory indicated
that in vitro-derived pre-compacted embryos are more susceptible to the effects of PGF2α
than compacted embryos. Presence of prostaglandin F2α receptors (FPr) in bovine
embryos will allow for new therapeutic strategies aimed at improving reproduction in
bovines. Therefore, in Experiment 1, two studies were performed to investigate any toxic
or negative effect of AL-8810, an FPr antagonist, on in vitro development of bovine
embryos. In this study, pre-compacted embryos were culture in: 1) 25 AL (25 nM AL8810 in KSOM-PVA; n= 94); 2) 50 AL (50 nM AL-8810 in KSOM-PVA; n= 94); 3) 100
AL (100 nM AL-8810 in KSOM-PVA; n= 94); and 4) CON (KSOM-PVA; n= 95).
Subsequently, pre-compacted embryos were cultured in: 1) 250 AL (250 nM AL-8810 in
KSOM-PVA; n=274); 2) 500 AL (500 nM AL-8810 in KSOM-PVA; n=274); 3) 1000
AL (1000 nM AL-8810 in KSOM-PVA; n= 282); and 4) CON (KSOM-PVA; n= 278). In
Experiment 1, embryos remained in their treatments until blastocyst assessment. Next, in
Experiment 2, the efficacy of AL-8810 on preventing detrimental effects of PGF2α on
pre-compacted embryos was investigated. In this experiment, pre-compacted embryos
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were cultured in: 1) 100 AL (100 nM AL-8810 in KSOM-PVA; n= 121); 2) 10 PGF (10
ng/mL of PGF2α in KSOM-PVA; n=91); 3) 100 AL + PGF (100 nM AL-8810 and 10
ng/mL of PGF2α in KSOM-PVA; n=116); and 4) CON (KSOM-PVA; n= 96).
Subsequently, pre-compacted embryos were cultured in: 1) 1000 AL (1000 nM AL-8810
in KSOM-PVA; n= 87); 2) 10 PGF (10 ng/mL of PGF2α in KSOM-PVA; n=87); 3) 1000
AL + PGF (1000 nM AL-8810 and 10 ng/mL of PGF2α in KSOM-PVA; n=84); and 4)
CON (KSOM-PVA; n= 84). In Experiment 2, embryos remained in their treatments for
approximately 48 h when development to morula was assessed. Results showed that
addition of 25, 50, 100 nM did not compromise embryonic development to blastocyst
compared to controls (61%, 56%, 55%, and 50% respectively). In addition, orthogonal
contrasts indicated that 100 nM AL-8810 improved development to blastocyst (100 AL=
61% vs. CON= 50%, P=0.01). Culture of embryos with 250, 500, 1000 nM AL-8810 did
not affect development to blastocyst (35%, 39% and 40%, respectively) when compared
to controls (38%). Finally, addition of 1000 nM AL-8810, but not 100 nM, to culture
medium of pre-compacted embryos exposed to PGF2α increased the ability of embryos to
undergo compaction 48 h later (1000 AL + PGF=51% vs. PGF=40%; P=0.05). In
conclusion, AL-8810 at a concentration of 1000 nM inhibits detrimental effects of PGF2α
on development of pre-compacted bovine embryos and may prove beneficial for other
assisted reproductive techniques in cattle.

2. Introduction
Inadequate reproductive efficiency has a tremendous impact in the economy of
dairy and beef producers. Moreover, early embryonic death in cattle represents 75 to 80%
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of all reproductive losses between fertilization and calving (Sreenan and Diskin, 1983).
Prostaglandin F2α (PGF2α), a derivate of arachidonic acid (Flint et al., 1986) and the
primary luteolytic hormone in ruminants (Goding, 1974; Braden et al., 1988; Okuda et
al., 2002) has been shown to decrease embryo quality and development and to lower
pregnancy rates in cows (Seals et al., 1998; Lemaster et al., 1999; Elli et al., 2001;
McNaughtan et al., 2002; Pugh et al., 2004; Purcell et al., 2004; Scenna et al., 2005). In
addition, PGF2α decrease embryonic development of rabbit, rat and bovine embryos in
vitro (Maurer and Beier, 1976; Breuel et al., 1993; Scenna et al., 2004).
The FPr is a seven transmembrane protein receptor coupled to a specific G protein
(Gq) mediating the formation of inositol triphospate (IP3) and diacylglycerol (DAG),
second messengers (Coleman et al., 1994) leading to an increase in intracellular calcium
levels and activation of protein kinase C (Wiltbank et al., 1989; Wiltbank et al., 1989;
Wiltbank et al., 1990). Downstream signaling are not well understood, but an
involvement of a Raf/MEK/MAPK signaling cascade followed by regulation of gene
transcription has been suggested by Chen et al. (1998). Moreover, several isoforms of the
FPr receptor have been characterized in bovine and ovine luteal cells (Ezashi et al., 1997;
Pierce et al., 1997; Ishii and Sakamoto, 2001; Sakamoto et al., 2002). A selective
antagonist for the FPr, AL-8810, has been well characterized by Griffin et al. (1999).
This antagonist has been shown to inhibit calcium mobilization and MAP kinase
activation induced after stimulation with several PGF2α agonists (Sharif et al., 2001;
Kelly et al., 2003; Sharif et al., 2003).
Recent studies from our laboratory have demonstrated the presence of
prostaglandin F2α receptor (FPr) mRNA and protein in bovine embryos (Scenna et al.
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2006). Presence of FPr in bovine embryos allows for the development of new therapeutic
strategies to improve embryo quality, development and survival in cows, which will
result in better reproductive efficiency and higher monetary earnings to the cattle
industry. Therefore, the objectives of this study were to 1) determine if AL-8810
possesses any toxic effect for in vitro culture of bovine embryos, and 2) to inhibit
detrimental effects of PGF2α on in vitro development of bovine embryos.

3. Experimental procedures
3.1. Materials
Dimethyl sulphoxide (DMSO), polyvinyl alcohol (PVA), bovine serum albumin
(BSA), percoll, penicillamine, hypotaurine, epinephrine and the majority of reagents used
for in vitro production of bovine embryos were purchased from Sigma Chemical, Inc. (St.
Louis, MO). Tissue culture medium-199, gentamicin, and penicillin-streptomycin were
purchased from Specialty Media, Inc. (Phillipsburg, NJ). Fetal bovine serum (FBS) was
obtained from BioWhittaker (Walkersville, MD). Folltropin-V and Vigro holding Plus
were purchased from Bioniche Life Sciences, Inc. (Belleville, ON). Ovaries were
purchased from Brown’s Packing Plant (Gaffney, SC). Media (HEPES-TALP, IVFTALP, and SPERM-TALP; Parrish et al., 1988) and KSOM (Edwards et al., 2005), were
prepared in the laboratory. Sperm characteristics were analyzed using a computerized
sperm analyzer (CASA) from Hamilton Thorne Biosciences (Beverly, MA).
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3.2. General procedures for in vitro production of bovine embryos
3.2.1. Oocyte collection
The procedures utilized for in vitro production of embryos (IVP) were
modifications of procedures previously described by Lawrence et al. (2004). Ovaries
obtained from an abattoir were packaged in thermoses and contained within a cooler
during air transport to the laboratory. Upon arrival to the laboratory, ovaries were
immediately washed with warm tap water equilibrated to arrival temperature of ovaries
(generally between 28 to 30 C°). Excess of tissue surrounding ovaries was removed
utilizing a scissor and ovaries were washed with warm tap water an additional time.
For oocyte recovery, ovaries were held firmly by clamping the base of the ovary
with a hemostat and checkerboard incisions were made across follicles (approximately 38 mm in diameter) using a scalpel blade. Ovaries were vigorously washed in oocyte
collection medium (OCM) in order to remove cumulus oocyte complexes (COCs)
contained within the follicles. Collection medium was filtered and rinsed using an Emcon
Filter unit (Vet Concepts, Spring Valley, WI) until medium was clear. Medium
containing COCs was poured into a gridded culture dish where searching of oocytes was
accomplished. Cumulus oocyte complexes were transferred to an “X” plate containing
OCM and washed four times to eliminate cellular debris. Cumulus oocyte complexes of
good quality were washed in oocyte maturation medium (OMM) and placed in groups of
approximately 50 COCs per well in a 4-well plate containing 500 μL OMM. Maturation
of oocytes was performed in an incubator at 5.5% CO2 in air at 38.5° C until time of
fertilization (approximately 24 h after placement in OMM). Maturation medium was
equilibrated in the incubator (5.5% CO2 in air at 38.5°C) the day before oocyte collection.
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3.2.2. Sperm preparation and in vitro fertilization
After oocyte maturation (22-24 h in OMM in an incubator at 5.5% CO2 in air at
38.5°C),

OMM

from

each

well

was

carefully

removed

and

25

μl

of

penicillamine/hypotaurine/epinephrine (PHE) and 500 μL of fertilization medium (IVFTALP) were added to each well. Two straws of semen from two bulls (140 Se5, 140
Se55, 30 SM002, CG30, SM 101), known to have high motility as well as producing high
cleavage and blastocyst percentages were used to fertilize oocytes for every replicate of
the study. Briefly, semen straws were removed from liquid nitrogen tank and placed in
water at 36.7°C for 45 sec. Each straw was then emptied on top of a discontinuous
Percoll density gradient (3 mL 45% percoll over 3 mL 90% percoll contained in a 15 mL
conical tube) and sperm was centrifuged at 760 g for 15 min in order to remove excess
extender, debris, and nonmotile sperm prior to fertilization. Sperm pellet present at the
bottom of the 90% fraction was collected and transferred to 10 mL SPERM-TALP and
centrifuged at 200 g for 8 min. Supernatant was removed and sperm pellet re-suspended
in 100 μL of modified IVF-TALP. Sperm concentration and motility were determined
using a CASA and sperm was added to each well at a final concentration of 500,000
motile sperm per well. Lastly, oocytes and sperm were incubated at 5.5% CO2 in air at
38.5°C for 18-22 h.

3.2.3 In vitro culture
Approximately 18-22 h post fertilization, putative zygotes (PZ) were denuded of
cumulus cells by vortexing. Putative zygotes were transferred to a 2 mL centrifuge tube
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containing 50 μL of HEPES-TALP and vortexed for 5 min. Recovered putative zygotes
were washed 4 times in HEPES-TALP before transferring groups of approximately 40-50
zygotes to each well of a 4-well plate containing 500 μL of KSOM culture medium per
well. Zygotes were placed in a humidified atmosphere of 5.5% CO2, 7% O2, and 87.5%
N2 at 38.5°C until desired stage of development and initiation of respective treatments.

3.3. Experiment 1: Determination of AL-8810 dose toxicity on in vitro embryo
development
AL-8810 is an 11β-fluoro analog of PGF2α which acts as a potent and selective
antagonist at the FP receptor. This compound has weak intrinsic activity on FPr in the
200-300 nM range. However, it fully antagonizes the activity of the potent FPr agonist
fluprostenol at these concentrations (Griffin et al., 1999). At a concentration of 1 to 2 μM,
AL-8810 inhibits several potent agonists at the cloned human ciliary body (Sharif et al.,
2002). In addition, AL-8810 does not inhibit the activity of prostaglandin E, D, I
receptors (Crider et al., 1998; Crider et al., 1998; Crider et al., 1999) suggesting a
selective antagonism at the FP receptor.
The effects of AL-8810 during in vitro embryo development in cattle have not
been studied. Therefore, two preliminary experiments were performed to determine
possible negative effects (or toxicity) of AL-8810 on embryonic development of in vitroproduced embryos cultured in KSOM-PVA (3 mg/mL, 0.3%) alone or in KSM-PVA with
the addition of 6 different concentrations of AL-8810.
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3.3.1. Preparation of AL-8810 stock and addition to the culture medium
Prior to the beginning of each experiment, the content of a vial containing 10 mg
of AL-8810 (Cayman Chemical Inc., Ann Arbor, MI; catalog# 16735) was reconstituted
and solubilized in DMSO (Primary Stock, 1000 μM AL-8810). Aliquots of 1 ml of
primary stock solution were stored at -80C° until needed. For each replicate, the primary
stock solution was diluted 1:10 in KSOM-PVA (Secondary Stock, 100 μM AL-8810) and
added to each experimental well (500 μl of equilibrated KSOM-PVA) to obtain final
concentrations of 25, 50, 100, 250, 500, and 1000 nM AL-8810. Control experimental
wells were prepared by adding the same concentration of DMSO (0.1%) used to prepare
the highest concentration of AL-8810 in KSOM-PVA.

3.3.2. Experimental design for Experiment 1
Procedures for oocyte collection, maturation, fertilization and embryo culture
were previously described under general methods. Pre-compacted 16- to 32-cell stage
embryos (approximately 97 h post IVF) were rapidly transferred to HEPES-TALP,
evaluated for quality (normal shape, defined blastomeres, extruded blastomeres,
cytoplasmic fragmentation, even cytoplasm), evenly sorted according to their quality,
washed rapidly in KSOM-PVA, and transferred to experimental treatments in a 4-well
plate. Experimental plates were placed in the incubator (5.5% CO2, 7% O2, and 87.5% N2
at 38.5°C) for 3 additional days when embryo development was determined using IETS
guidelines for classification of bovine embryos (Stringfellow and Seidel, 1998). Data for
development to blastocyst were analyzed using a randomized block design model with
replicate (a 4-well plate with each of its wells containing one treatment; a group of
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embryos in each well was considered an experimental unit) as random effect and
treatment as fixed effect performing mixed procedures of SAS software (SAS 9.1, SAS
Institute Inc., Cary, NC). In addition, orthogonal contrasts were performed to determine
differences on development to blastocyst among treatments.
A total of 5 replicates were utilized to investigate the effects of 25, 50, 100, and 0
nM of AL-8810 on in vitro embryo development. In each of these replicates, precompacted embryos at 16- to 32-cell stage received one of the following culture
treatments: 1) 25 AL (25 nM AL-8810 in KSOM-PVA; n= 94); 2) 50 AL (50 nM AL8810 in KSOM-PVA; n= 94); 3) 100 AL (100 nM AL-8810 in KSOM-PVA; n= 94); and
4) 0 CON (KSOM-PVA; n= 95; Figure 6).
A total of 11 replicates were used to investigate the effects of 250, 500, 1000, and
0 nM of AL-8810 on in vitro embryo development. In each of these replicates, precompacted embryos at 16- to 32-cell stage received one of the following culture
treatments: 1) 250 AL (250 nM AL-8810 in KSOM-PVA; n=274); 2) 500 AL (500 nM
AL-8810 in KSOM-PVA; n=274); 3) 1000 AL (1000 nM AL-8810 in KSOM-PVA; n=
282); 0 CON (KSOM-PVA; n= 278; Figure 7).

3.4. Experiment 2: Does AL-8810 prevent detrimental effects of PGF2α on in vitro
produced embryos?
3.4.1 Preparation of prostaglandin F2α stocks
Prior to the beginning of each experiment, prostaglandin F2α (1 mg; Cayman
Chemical Inc., Ann Arbor, MI; catalog# 16010) was solubilized in 10 mL of DMSO each
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Pre-compacted
IVM

Blastocyst

25 nM AL-8810; n= 94

IVF

50 nM AL-8810; n= 94

Oocyte
Collection

100 nM AL-8810; n= 94

Denuding

Control; n= 95

Figure 6. Experimental design for determination of 25, 50, and 100 nM AL-8810 toxicity
on in vitro embryo development of bovine embryos. Treatments were 25 nM AL-8810
(25 AL), 50 nM AL-8810 (50 AL), 100 nM AL-8810 (100 AL), and Control.
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250 nM AL-8810; n= 274
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500 nM AL-8810; n= 274

Oocyte
Collection

Denuding

1000 nM AL-8810; n= 282
Control; n= 278

Figure 7. Experimental design for determination of 250, 500, and 1000 nM AL-8810
toxicity on in vitro embryo development of bovine embryos. Treatments were 250 nM
AL-8810 (250 AL), 500 nM AL-8810 (500 AL), 1000 nM AL-8810 (1000 AL), and
Control.
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(Stock #1; 100,000 ng/mL). Then, 30 µL aliquots were stored at -80C° until needed.
Based on manufacturer’s instructions, once PGF2α has been reconstituted in DMSO, the
storage life of PGF2α at -80°C is 6 months. For each replicate of the experiment, 12.5 µL
of PGF2α stock #1 were combined with 987.5 µL of KSOM-PVA (stock #2; 1.25 ng of
PGF2α per µL). Next, 4 µL of stock #1 were added to each experimental well (500 µL of
equilibrated KSOM-PVA or 500 μl of 100 nM AL-8810) to obtain a final concentration
of 10 ng/mL of PGF2α in the culture medium. It is important to mention that PGF2α was
added at least 30 min after the embryos were placed in 100 nM or 1000 nM AL-8810 to
allow the interaction of the FPr antagonist with its receptors at the plasma membrane.
Four-well plates containing 500 µL of KSOM-PVA in each well were equilibrated in an
incubator (5.5% CO2, 7% O2, and 87.5% N2 at 38.5°C) for at least 12 h before initiation
of treatments.

3.4.2. Experimental design for Experiment 2
Previous data from our laboratory demonstrated that addition of PGF2α to the
culture medium of pre-compacted in vitro produced embryos reduced the ability of
embryos to undergo compaction. On the other hand, exposure of compacted in vitro
produced embryos to PGF2α did not compromise the ability of embryos to reach
blastocyst stage (Scenna et al., 2006). Therefore, two experiments were performed to
determine the ability of AL-8810 on preventing detrimental effects of PGF2α on in vitro
produced pre-compacted embryos.
Procedures for oocyte collection, maturation, fertilization and embryo culture
were previously described under general methods. Embryos at the 16- to 32-cell were
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rapidly transferred to HEPES-TALP, evaluated for quality (normal shape, defined
blastomeres, extruded blastomeres, cytoplasmic fragmentation, even cytoplasm), evenly
sorted according to their quality, washed rapidly in KSOM-PVA, and transferred to
experimental treatments in a 4-well plate.
A total of 5 replicates were used to evaluate effects of 100 nM AL-8810 on
embryonic development of embryos cultured in medium containing PGF2α. Precompacted embryos at 16- to 32-cell embryos received one of the following culture
treatments: 1) 100 AL (100 nM AL-8810 in KSOM-PVA; n= 121); 2) PGF-10 (10 ng/mL
of PGF2α in KSOM-PVA; n=91); 3) 100 AL + PGF-10 (100 nM AL-8810 and 10 ng/mL
of PGF2α in KSOM-PVA; n=116); 4) CON (KSOM-PVA; n= 96; Figure 8).
Subsequently, a total of 3 replicates were performed to determine the effects of 1000 nM
AL-8810 on embryonic development of pre-compacted embryos exposed to PGF2α. In
this study, 16-32-cell embryos were cultured in: 1) 1000 AL (1000 nM AL-8810 in
KSOM-PVA; n= 87); 3) PGF-10 (10 ng/mL of PGF2α in KSOM-PVA; n=87); 3) 1000
AL + PGF-10 (1000 nM AL-8810 and 10 ng/mL of PGF2α in KSOM-PVA; n=84); 4)
CON (KSOM-PVA; n= 84; Figure 9). It is important to mention that PGF2α was added at
least 30 min after the embryos were placed in 1000 nM AL-8810 to allow the interaction
of the FPr antagonist with its receptors at the plasma membrane.
In each of these two experiments, experimental plates were placed in the
incubator (5.5% CO2, 7% O2, and 87.5% N2 at 38.5°C) for 48 h and embryo development
to compact morula was determined using IETS guidelines for classification of bovine
embryos. Collected data were analyzed by using mixed procedures of SAS software
(SAS 9.1, Cary, NC). Data for development to compact morula were analyzed using a
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Compact Morula

Pre-compacted
IVM

100 AL; n= 121

IVF

PGF-10; n= 91

Oocyte
Collection

Denuding

100 AL+ PGF-10; n= 116
Control; n= 96

Figure 8. Experimental design for evaluation of AL-8810 efficacy on inhibiting
prostaglandin F2α effects on pre-compacted bovine embryos. Treatments were 100 nM
AL-8810 (100 AL), 10 ng/mL prostaglandin F2α (PGF-10), 100 nM AL-8810 + 10 ng/mL
prostaglandin F2α, (100 AL + PGF-10) and control.
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Pre-compacted
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1000 AL; n= 87

IVF

PGF-10; n= 87

Oocyte
Collection

Denuding

1000 AL+ PGF-10; n= 84
Control; n= 84

Figure 9. Experimental design for evaluation of AL-8810 efficacy on inhibiting
prostaglandin F2α effects on pre-compacted bovine embryos. Treatments were 1000 nM
AL-8810 (1000 AL), 10 ng/mL prostaglandin F2α (PGF-10), 1000 nM AL-8810 + 10
ng/mL prostaglandin F2α (1000 AL + PGF-10) and control.
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randomized block design model with replicate (a 4-well plate with each of its wells
containing one treatment; a group of embryos in each well was considered an
experimental unit) as random effect and treatment as fixed effect performing mixed
procedures of SAS software (SAS 9.1, SAS Institute Inc., Cary, NC). In addition,
orthogonal contrasts were performed to determine differences on development to
compact morula stage among treatments.

4. Results
Data from Experiment 1 indicated that culture of pre-compacted in vitro produced
embryos in medium containing 25, 50, and 100 nM of the specific FPr antagonist AL8810, did not have a negative (or toxic) effect on embryonic development when
compared to embryos cultured in control medium (61%, 56 %, 55%, and 50%,
respectively; Figure 10). Moreover, addition of AL-8810 at a concentration of 100 nM to
the culture medium increased blastocyst formation when compared to control medium
(61% vs. 50%, respectively, P=0.01). Similarly, addition of AL-8810 to the culture
medium at a concentration of 250, 500, and 1000 nM did not cause any detrimental
effects on the ability of embryos to reach blastocyst stage when compared to embryos
cultured in control medium (40%, 39%, 35% and 38%, respectively, Figure 11).
In Experiment 2, no differences in embryonic development of pre-compacted
embryos to morula stage between 100 AL, PGF-10, 100 AL+PGF and CON groups were
observed (55%, 44%, 55%, and 51%; respectively; Figure 12). In addition, orthogonal
contrast showed a strong tendency of 100 AL + PGF-10 and 100 AL to increase
development to compact morula when compared to embryos treated with PGF2α (55% for
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Figure 10. Percentage of pre-compacted embryos that continued development to
blastocyst in Experiment 1 after culture in medium containing 25, 50, 100 nM AL-8810
or control medium. a,b Values with different superscripts differ; P<0.005. Standard errors
were ± 5.2 100 nM AL-8810, 25 nM AL-8810 and control, and ± 5.34 for 50 nM AL8810.
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Figure 11. Percentage of pre-compacted embryos that continued development to
blastocyst in Experiment 1 after culture in medium containing 250, 500, 1000 nM AL8810 or control medium. Standard errors were ± 3.63 for each treatment.
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Figure 12. Percentage of pre compacted embryos that continued development to compact
morula in Experiment 2. Treatments in Experiment 2a included: 100 nM AL-8810 (100
AL), 10 ng/mL prostaglandin F2α (PGF-10), 100 nM AL-8810 + 10 ng/mL prostaglandin
F2α (100 AL + PGF-10), and control (Con). Treatments in Experiment 2b were: 1000 nM
AL-8810 (1000 AL), 10 ng/mL prostaglandin F2α (PGF-10), 1000 nM AL-8810 + 10
ng/mL prostaglandin F2α (1000 AL + PGF-10), and control (Con). a,bValues differ
between treatments; P=0.05. Standard errors in Experiment 2a were ± 4.8, 4.8, 4.8, and
5.3 for 100 AL, PGF-10, 100 AL + PGF-10, and Con, respectively. Standard errors in
Experiment 2b were ± 4.6, 4.6, 5, and 4.6 for 1000 AL, PGF-10, 1000 AL + PGF-10 and
Con, respectively.
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both treatments vs. 44% in PGF-10). In Experiment 2, no differences on development to
morula stage were observed between 1000 AL, 1000 AL+PGF and CON (51%, 51% and
52%, respectively; P>0.05; Figure 12). However, previous exposure of embryos to AL8810 before addition of PGF2α to the treatment well improved embryonic development to
compact morula (1000 AL+PGF=51% vs. PGF=40%; P<0.05; Figure 12).

5. Discussion
Experiments 1 indicated that addition of various concentrations of an FPr
antagonist, AL-8810, to the culture medium of in vitro-produced embryos did not result
in lowered embryonic development. Furthermore, AL-8810 at a concentration of 100 nM
in the culture medium improved the percentage of pre-compacted embryos reaching
blastocyst stage. Since our culture system consisted in modified KSOM medium without
the addition of animal proteins (bovine serum albumin), the positive effects of 100 nM of
AL-8810 on embryonic development when compared to control medium was relatively
unexpected. Several studies have indicated that embryos from different species are able
to synthesize a wide range of prostaglandins (Shemesh et al., 1979; Hyland et al., 1982;
Stone et al., 1986; Harper et al., 1989; Sayre and Lewis, 1993). Even though the presence
of cyclooxygenase-1 (COX-1) cyclooxygenase-2 (COX-2) enzymes in bovine embryos
has not been determined, studies in other species indicated that early stage embryos
express these enzymes and are able to produce prostaglandins. For example, human
embryos at early stage of development predominantly express COX-1, whereas 8-cell to
blastocyst stage embryos express mostly COX-2 (Wang et al., 2002). Similarly, Parr et al.
(1988) and Tan et al. (2005) demonstrated the presence of COX-1 and COX-2 in rat and
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mouse embryos, respectively. In vitro-produced bovine embryos may be able to secrete
discrete amounts of PGF2α to the culture medium, which in turn could have a negative
effect on embryonic development. This may explain in part the beneficial effects
observed on embryonic development after culturing embryos in medium containing 100
nM of AL-8810 when compared to control medium.
In Experiment 2, previous exposure of pre-compacted embryos to the FPr
antagonist AL-8810 at a concentration of 1000 nM in the culture medium inhibited
detrimental effects of PGF2α on embryonic development to morula stage. Similarly,
several in vitro studies showed the efficacy and inhibitory actions of AL-8810 on
inhibiting PGF2α effects after binding to its receptors. For example, previous exposure of
mouse fibroblast to AL-8810 abolished the production of IP3 associated with FPr
stimulation by FPr agonist (fluprostenol) or its endogenous ligand (PGF2α) (1999).
Furthermore, several other studies also demonstrated the efficacy of AL-8810 on
inhibiting the activation of FPr by several PGF2α agonists (Sharif et al., 2002; Kelly et al.,
2003; Sharif et al., 2003; Sharif et al., 2003).
To date, the mechanism/s of action of PGF2α on bovine embryos has/have not
been documented in the literature. However, based on the recent discovery of FPr in
bovine embryos (Scenna et al., 2006), we can hypothesize that downstream signaling
events occurring after PGF2α binds to its receptor are interfering with several mechanisms
leading to compaction of bovine embryos. Compaction represents a key critical event for
continued embryonic development. During this process, formation of junctional apical
complexes (formed by E-cadherin and tight junctions) between outer blastomeres allows
polarization and differentiation of these blastomeres into trophectoderm cells. On the
97

other hand, lack of junctional complexes and polarization of inner blastomeres allows
these blastomeres to differentiate into the inner cell mass (Fleming et al., 2001). The
junctional complexes between trophectoderm cells facilitate fluid accumulation within
the blastocoele cavity and directly contributes to the formation of the blastocyst and its
subsequent hatching from the zona pellucida (Watson et al., 1992; Fleming et al., 2001).
It is tempting to hypothesize that PGF2α may impair the ability of pre-compacted
embryos to undergo compaction by disassembling, destructing, or decreasing synthesis of
cell-cell adhesion molecules (E-cadherin and tight junctions) between blastomeres.
Indeed, studies have indicated that overexpression of COX-2 and therefore, an increase in
prostaglandin synthesis, were associated with a disruption of cell-cell adhesion
molecules, tumor formation, tumor invasion and metastasis (Hida et al., 1998; Takahashi
et al., 2002). On the other hand, treatment of cancer cell lines with COX-2 specific
inhibitors resulted in increased E-cadherin expression and inhibition of cell growth (Noda
et al., 2002; Erdogru et al., 2005; Dohadwala et al., 2006). In addition, upregulation of
intracellular Ca++ (an effect associated with PGF2α actions on target cells) leads to
contraction of Ca++ calmodulin-dependent actin-myosin filaments which in turn alters
cellular shape, opens up TJ’s and increases paracellular permeability (Lindmark et al.,
1998). Moreover, protein kinase C (a protein activated by PGF2α on target cells) and the
protein kinase C activator phorbol 12-myristate 13-acetate (PMA) have been shown to
increase cellular permeability by opening of tight junctions (Sjo et al., 2003; Angelow et
al., 2005). Furthermore, it has been shown that PGF2α stimulates the synthesis of matrix
metalloproteinases (MMP’s; (Lindsey et al., 1996; Weinreb et al., 1997) which can in
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turn induce proteolytic degradation of tight junction proteins and result in increase
epithelial permeability (Wachtel et al., 1999; Lohmann et al., 2004; Gurney et al., 2006).
Alterations in E-cadherin or tight junctions caused by the effects of PGF2α on the
embryo may result in an impairment of the embryo to compact and form a blastocoele
cavity, two critical steps for continued development. In fact, homozygous null mutants
mouse embryos for the E-cadherin gene initially compacted (an event attributed to the
presence of maternal or oogenetic E-cadherin proteins) but then proceeded to decompact,
with cells becoming apolar due to interference in the formation of apical junctional
complexes (Laure et al., 1994; Riethmacher et al., 1995). Moreover, these embryos failed
to develop a normal blastocoel cavity and did not hatch from the zona pellucida
(Riethmacher et al., 1995). Further evidence of the importance of E-cadherin on
compaction was observed when mouse blastomeres decompacted after treatment with
antibodies against Ca++-dependent molecules (Reima, 1990). Recently, targeted
disruption of the E-cadherin gene in bovine pre-attachment embryos by RNA interference
technology resulted in less embryos reaching compact morula or blastocyst stage
(Nganvongpanit et al., 2006). These findings indicate a critical role of E-cadherin not
only during compaction, but on further embryonic development in bovine embryos.
In conclusion, addition of a selective FPr antagonist, AL-8810, to the culture
medium of in vitro produced embryos inhibited detrimental effects of PGF2α on embryo
development without toxicity. These findings suggest that the effects of PGF2α on bovine
embryos are in part caused by receptor-mediated events and downstream signaling
cascades. We hypothesized that binding of PGF2α to its receptor causes downstream
signaling events (mobilization of intracellular Ca++, activation of PKC and MAPK’s) that
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may decrease the embryos’ ability to compact by causing disruption, destruction or
inhibition of synthesis of adherens and tight junctions between blastomeres. Moreover,
addition of AL-8810 to the culture medium may become a standard procedure for
enhancing development of in vitro produced mammalian embryos.
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CHAPTER 5
PREGNANCY RATES OF RECIPIENT ANIMALS FOLLOWING
APPLICATION OF A SELECTIVE PROSTAGLANDIN F2Α
RECEPTOR ANTAGONIST DURING EMBRYO RECOVERY

1. Abstract
In the presence of supplemental progesterone, prostaglandin F2α (PGF2α) has been
shown to directly reduce embryo quality, development and pregnancy rates in cattle. The
aim of this study was to evaluate addition of a PGF2α receptor (FPr) antagonist to
collection medium on pregnancy rates after transfer of embryos to recipient animals. An
initial experiment was performed to determine embryonic development and gene
expression of in vivo-derived frozen-thawed embryos cultured in KSOM-PVA medium
with 1000 nM AL-8810 (AL, n= 94), 1000 nM AL-8810 and 10 ng/mL PGF2α (AL+PGF,
n= 94), 10 ng/mL PGF2α (PGF, n= 94), or serving as controls (CON, n= 91). Embryos
remained in their treatment for a 30-h period, at the end of which embryo development
per treatment was recorded. Embryos from each treatment group were then processed for
analysis of Na+/K+ ATPase α1 and ZO-1 transcripts by reverse transcription real time
PCR. In the subsequent study, embryos were recovered from superovulated donor cows
on day 7 after artificial insemination with medium containing 1000 nM AL-8810 (FlushAL) or without (Flush-Con). Following collection in their respective treatment, embryos
were classified by stage and quality and maintained in holding medium with 1000 nM
AL-8810 or without until freezing, then transferred following thawing to suitable
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recipients. Results from the initial experiment indicated that culture of in vivo-derived
bovine embryos in medium containing AL-8810 improved blastocyst development
compared to PGF (58% vs. 46%; P=0.05). In addition, a strong tendency on embryo
development was observed in AL+PGF compared to PGF treatment group (57% vs. 46%;
P=0.07). Blastocyst development of embryos in CON did not differ when compared to
embryos in PGF (55% vs. 46%; P=0.12). Relative abundance of Na+/K+ ATPase α1 and
ZO-1 transcripts among treatments did not differ. Recovery of embryos with medium
containing AL-8810 increased pregnancy rates following embryo transfer when
compared to embryos recovered without AL-8810 (Flush-AL= 46% ± 0.06 vs. FlushCon= 36% ± 0.06; P=0.04). In conclusion, the addition of an FPr antagonist prevented
detrimental effects of PGF2α on in vitro development of in vivo-derived bovine embryos.
Moreover, recovery of embryos with flushing medium containing an FPr antagonist
improved pregnancy rates after transfer of embryos to recipient cows.

2. Introduction
Multiple ovulation and embryo transfer (MOET) programs in livestock
production are utilized as a means for rapid acquisition of superior genetics and to
increase productive life of elite donor cows by increasing the number of valuable
progeny. Currently, MOET programs in cattle are used around the world, with more than
500,000 embryos being transferred annually (Thibier, 2000). Efficiency of such programs
in cattle depends on several factors associated with donor’s response to superovulation
(Seidel, 1984), number of viable embryos recovered per collection (Donaldson and Perry,
1983; Hasler et al., 1983; Seidel, 1984; Stroud and Hasler, 2006), and the percentage of
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recipient animals establishing a pregnancy after transfer (Leibo, 1986; Hasler, 1992;
Nibart and Humblot, 1997; Lester and McNew, 1999; Hasler, 2001, 2003).
Manipulation of the reproductive tract during embryo transfer results in PGF2α
release from the uterine endometrium (Scenna et al., 2005). Other studies have also
reported a release of PGF2α following uterine manipulation in mares (Kask and Odensvik,
1995), sows (Kunavongkrit et al., 1984) and cows (Wann and Randel, 1990). Moreover,
several studies have shown detrimental effects of elevated PGF2α on in vitro development
of rat, rabbit and bovine embryos (Maurer and Beier, 1976; Breuel et al., 1993; Scenna et
al., 2004). Elevated PGF2α has also been shown to have detrimental effects on embryonic
development, quality and hatching ability of embryos and pregnancy rates in cows, even
in the presence of supplemental progesterone (Schrick et al., 1993; Buford et al., 1996;
Lemaster et al., 1999; Elli et al., 2001; Hockett et al., 2004; Sales et al., 2004).
Furthermore, administration of inhibitors of PGF2α synthesis at the time of embryo
transfer to recipient animals increased pregnancy rates (Elli et al., 2001; McNaughtan et
al., 2002; Pugh et al., 2004; Purcell et al., 2004; Scenna et al., 2005).
The objectives of this study were 1) to determine in vitro development and gene
expression of two relevant genes involved in blastocyst formation (Na+/K+ ATPase α1
and ZO-1) of in vivo-derived bovine embryos cultured with a selective FPr antagonist;
and 2) to determine if addition of a FPr antagonist to collection medium during recovery
of bovine embryos increased pregnancy rates following transfer of these embryos to
recipient cows. Improving pregnancy rates after embryo transfer in cows using an FPr
antagonist will allow for development of new therapeutic techniques in other species,
including humans, to increase reproduction and success rates.
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3. Materials and Methods
3.1. Experimental procedures to determine the effects of PGF2α and AL-8810 on
development and relative abundance of genes associated with compaction
3.1.1. Preparation of treatments
3.1.1.1. Preparation of AL-8810
Prior to the beginning of each experiment, the content of a vial containing 10 mg
of AL-8810 (Cayman Chemical Inc., Ann Arbor, MI; catalog# 16735) was reconstituted
and solubilized in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO; Primary
Stock, 1000 μM AL-8810) to obtain a primary Stock solution of 1000 μM AL-8810.
Aliquots containing 1 mL of primary stock solution were stored at -80°C until needed.
For each replicate, the primary stock solution was diluted 1:10 in KSOM-PVA (0.3%;
Secondary Stock, 100 μM AL-8810) and added to the experimental wells (495 μl of
equilibrated KSOM-PVA) to obtain a final concentration of 1000 nM AL-8810 in the
culture medium.

Control experimental wells were prepared by adding the same

concentration of DMSO (0.1%) used to prepare AL-8810 in KSOM-PVA.

3.1.1.2 Preparation of prostaglandin F2α
Prior to the beginning of each experiment, prostaglandin F2α (5 mg; Cayman
Chemical Inc., Ann Arbor, MI; catalog# 16010) was solubilized in 1 mL of DMSO each
(Stock #1; 5,000 μg/mL). Then, 20 µL aliquots were stored at -80°C until needed. For
each replicate of the experiment, 10 µL of PGF2α stock #1 were combined with 990 µL of
KSOM-PVA (stock #2: 50 μg/mL). Next, 10 µL of stock #2 were combined with 490 μL
of KSOM-PVA (stock #3: 1 μg/mL or 1 ng/μL). Finally, 5 μL of stock#3 were added to
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each experimental well (495 µL of equilibrated KSOM-PVA) to obtain a final
concentration of 10 ng/mL of PGF2α in the culture medium. Four-well plates with
KSOM-PVA in each well were equilibrated in an incubator (5.5% CO2, 7% O2, and
87.5% N2 at 38.5°C) for at least 12 h before preparation of treatments.

3.1.2. Assignment of treatments
In vivo-derived bovine embryos were thawed and sorted by stage of development
and quality according to the IETS guidelines for classification of bovine embryos
(Stringfellow and Seidel, 1998). Similar groups of embryos at the morula and early
blastocyst stage of quality grade 1, 2 or 3 were washed three times in HEPES-TALPPVA (0.3%) and once in KSOM-PVA (0.3%) and randomly transferred to one of four
treatments: 1) 1000 AL (1000 nM AL-8810 in KSOM-PVA, n=94); 2) 1000 AL + PGF10 (1000 nM AL-8810 + 10 ng/mL PGF2α in KSOM-PVA, n=94); 3) PGF-10 (10 ng/mL
PGF2α in KSOM-PVA, n=94); and 4) CON (KSOM-PVA, n= 91; Figure 1) in a 4-well
plate and placed in the incubator (5.5% CO2, 7% O2, and 87.5% N2 at 38.5°C). Three
replicates were utilized for this experiment. It is important to mention that PGF2α was
added at least 30 min after the embryos were placed in 1000 nM AL-8810 to allow the
interaction of the FPr antagonist with its receptors before addition of PGF2α.
After culturing embryos for 30 h, embryos from each treatment were placed in
HEPES-TALP-PVA (0.1%) and development to blastocyst stage was recorded. Next,
each treatment group (approximately 30 embryos) was washed 3 times in HEPES-TALPPVA (0.1%), loaded in 2.5 μL of HEPES-TALP-PVA (0.1%) and transferred to 25 μL of
RNA lysis buffer (Arcturus, Mountain View, CA) and stored at -80° C until use.
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3.1.3. Isolation of RNA
Total RNA from each treatment group was isolated using the PicoPure RNA
isolation Kit (Arcturus, Mountain View, CA) as per the manufacturer’s instructions.
Briefly, RNA was mixed with 70% ethanol by gently pipetting and the mixture was
added to an RNA purification column. DNAse treatment was performed by addition and
incubation of DNase I enzyme (Qiagen, Valencia, CA) for 15 min at room temperature in
the RNA purification columns. Several washes of the columns were performed previous
to elution of RNA from the column by using 12 μL elution buffer.

3.1.4. Reverse transcription
Isolated RNA from bovine embryos and bovine tongue epithelium was reversed
transcribed into complementary DNA in a total volume of 20 μL. The reaction mixture
consisted of 1X RT buffer, 5 mM MgCl2, 1 mM of each dNTP, 0.25 nM random primers,
20 iu RNase inhibitor, and 100 IU moleney murine leukaemia virus reverse transcriptase
(MMLV-RT). The RT reaction was carried out at 25°C for 10 min, 42°C for 1 h followed
by a denaturation step at 99°C for 5 min and flash cooling to 4°C. Controls for genomic
DNA contamination were prepared by emitting reverse transcriptase enzyme in the RT
reaction.

3.1.5. Real time PCR
Polymerase chain reaction was performed using the iCycler iQTM Real-Time PCR
detection system (Bio-Rad, Hercules, CA) and the iQTM SYBR Green Supermix (BioRad, Hercules, CA). The PCR reaction mixture consisted of 25 μL 1X iQ Supermix (100
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mM KCl, 40 mM Tris-HCl pH 8.4, 0.4 mM of each dNTP, iTaq DNA Polymerase 50
units/ml, 6 mM MgCl2, SYBR Green I, 20 nM fluorescein, and stabilizers), 1 μM
concentration of forward and reverse primers (Table 2) for β-actin (Rambeaud et al.,
2006), Na+/K+ ATPase α1 (Wrenzycki et al., 2003), and ZO-1, nuclease free water, and
cDNA template from each RT reaction. Negative control for each embryo sample
consisted of PCR amplification of RT negative reactions or mix without cDNA (no
template). The real time PCR protocol included an initial step of 95°C for 15 min,
followed by 40 cycles of 95°C for 15 sec, 55°C for 30 sec, and 72°C for 30 sec.
Fluorescence data was acquired during the elongation step. Since the melting curve of
PCR products is sequence specific, it is used to identify PCR products. Melting protocol
was performed by holding temperature at 45°C for 60 sec and then heating from 45 to
94°C, holding at each temperature for 10 sec while monitoring fluorescence. Product
identity was also confirmed by ethidium-bromide-stained 2% agarose gel electrophoresis
in 1X TBE (90 mM Tris, 90 mM borate, 2 mM EDTA, pH 8.3) visualized using a gel doc
apparatus (Bio-Rad, Hercules, CA) and by target sequencing (University of Tennessee
Molecular Biology Core Facility).

3.1.6. Statistical analysis
Collected data for ZO-1, and Na+/K+ ATPase α1 gene expression in each
treatment were computed using the 2-∆∆Ct method described by Livak and Schmittgen
(2001) and expressed as fold change in gene expression relative to control embryos
samples after normalizing for β-actin gene expression. Data for mRNA expression and
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Table 2. Details of primers used for RT-RT-PCR.

Gene
Na+/K+
ATPase α1

GenBank
Accesion
Number
NM_012504

Sequence

Location

5’-acctgttgggcatccgagagac-3’
5’-agggaaggcacagaaccacca-3’

2882–2903
3196–3217

Fragment
size (bp)
336

ZO-1

L14837

5’-gtctgccattacacggtcct-3’
5’-ggcttaaatccaggggagtc-3’

3803-3822
3921-3940

138

β-Actin

AY141970.1

5’-cggcattcacgaaactacct -3’
5’-gggcagtgatctctttctg-3’

855-875
978-997

143
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development to blastocyst from a total of 3 replicates were analyzed using a randomized
block design model with replicate (a 4-well plate with each of its wells containing one
treatment; a group of embryos in each well was considered an experimental unit) as
random effect and treatment as fixed effect performing mixed procedures of SAS
software (SAS 9.1, SAS Institute Inc., Cary, NC). In addition, orthogonal contrasts were
performed to determine differences on development to blastocyst among treatments.

3.2. In vivo production of embryos
3.2.1. Preparation of AL-8810
AL-8810 (Cayman Chemical Inc., Ann Arbor, MI; 10 mg) was reconstituted and
solubilized in dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO; Primary Stock,
1000 μM AL-8810) and aliquots containing 1 mL of primary stock solution were stored
at -80°C until needed. For each liter of flushing medium, 1 mL of primary stock solution
was added to obtain a final AL-8810 concentration of 1000 nM (Flush-AL1000).
Similarly, 1 mL of DMSO was added to each liter of flushing medium (Flush-Con) to
obtain the same amount of diluent (0.1%) as in the treatment flushing medium. In
addition, an aliquot containing 1 mL of a ten fold dilution of the primary stock solution in
DMSO was added to each liter of flushing medium to obtain a final AL-8810
concentration of 100 nM (Flush-AL100).

3.2.2. Estrous cycle synchronization and superovulation
On day 5 after CIDR insertion (day 1; Eazi-Breed CIDR; Pfizer Animal Health,
Kalamazoo, MI), embryo donors started a superovulation program consisting of
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administration of pFSH (range of 162-400 mg i.m.; Folltropin-V, Bioniche, Belleville,
Ontario, Canada) in decreasing doses twice daily for 4 days. Luteolysis was induced by
administration of two doses of prostaglandin F2α (500 μg cloprostenol; Estrumate,
Schering-Plough, Kenilworth, NJ; 12 h before and at the time of CIDR removal, day 9).
Cows were fitted with Heatwatch® detectors (DDX, Boulder, CO) for estrous detection in
addition to visual surveillance twice daily for 30 min. Cows were artificially inseminated
with 1 unit of frozen-thawed semen at 12 h after standing estrus and again 12 h later.

3.2.3. Embryo recovery and freezing
Collection of embryos from donor cows (Angus breed) was performed 7 days
after detection of estrus by placing a silicone catheter (Bioniche, Belleville, Ontario,
Canada) through the cervix and up to the uterus body (Drost et al., 1976). The uterus was
flushed several times with Vigro Complete Flush Solution (Bioniche, Belleville, Ontario,
Canada), containing either 100 nM AL-8810 (Flush-AL100), 1000 nM AL-8810 (FlushAL1000) or dimethyl sulfoxide (DMSO; Flush-Con). Collected flush medium was
filtered through a 0.22 μm EM-Con filter (Veterinary Concepts Incorporated, Spring
Valley, WI) and searched for the presence of embryos. Embryos collected with FlushAL100, Flush-AL1000 or Flush-Con were placed into holding medium (Vigro Holding
Plus; Bioniche, Belleville, Ontario, Canada) with either100 nM AL-8810, 1000 nM AL8810 or DMSO, respectively, and scored for quality and stage accordingly to the
International Embryo Transfer Society guidelines (Stringfellow and Seidel, 1998).
Following a 3X wash procedure in holding medium, embryos were frozen using 1.5 M
ethylene glycol (Vigro Ethylene Glycol Freeze Plus; Bioniche, Belleville, Ontario,
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Canada). Briefly, after scoring for stage and quality, embryos were placed for 5 min in
1.5 M ethylene glycol. Embryos were then individually loaded into 0.25 mL straw and
placed at -6°C in an automatic freezing unit (CL 5500; Cryologic, Mulgrave, Victoria,
Australia). The freezing program consisted in holding embryos at -6°C for 10 min
(seeding induced after 2 min at -6°C) followed by a descending freezing curve of
0.5°C/min until reaching -32°C. Embryos remained at -32°C for 10 min and then were
plunged into liquid nitrogen for final storage. Statistical analysis did not show differences
in pregnancy rates following transfer between Flush-AL100 and Flush-AL1000;
therefore, both treatment groups were combined as Flush-AL.

3.2.4. Embryo transfer
A total of 619 transfers into recipient cows (Registered Angus and Commercial
[Angus X British, Continental, or Bos Indicus]) were performed in a two year period
from February to May at four different locations in three states (Arkansas, Tennessee,
and Texas). Recipients were in moderate body condition, multiparous, and provided ad
libitum access to minerals, water and supplemental feed. Due to donor X semen
interactions determined after transfer (Schrick & Saxton, unpublished data), only 425
recipients were used for statistical analysis. Transfer data were included from the May
2006 Arkansas study in which recipients were improperly vaccinated with a modifiedlive vaccine during synchronization. Even though pregnancy rates were reduced in all
animals across treatments for this replicate, the trend in pregnancy rates was similar to all
other locations and thus, data were included in the final analyses. Animals that responded
to estrus synchronization and had an acceptable corpus luteum were used as embryo
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recipients 7 days (range 6-7.5 days) after detection of estrous. Briefly, animals were
restrained in a cattle handling facility and location of the corpus luteum was determined
by palpation per rectum or ultrasonography (Aloka 500 ultrasound unit equipped with a
7.5MHz linear transducer; Corometrics Medical System, Wallingford, CT). Prior to
embryo transfer, animals received an epidural injection of 2% lidocaine (2.5 ml; Lidoject;
Burns Veterinary Supply, Inc., Westbury, NY) and the perineal region was washed with
povidone solution. Embryos were thawed and non-surgically transferred to the upper
third of the uterine horn ipsilateral to the CL (Schrick et al., 1993). Pregnancy rates were
determined 30 to 60 days following transfer by ultrasonography or by palpation per
rectum.

3.2.5. Statistical analysis
Data were arranged in a randomized block design. Pregnancy rates (%), embryo
quality and stage variables were evaluated. Data pertaining to pregnancy rates were
analyzed using generalized linear mixed models (Proc Glimmix; SAS version 9.1, 2003;
SAS Institute Inc., Cary, NC). Data are presented as least squares means (± SEM). A
model procedure that included flush treatment (Flush-AL or Flush-Con), quality (1 or 2),
and stage (morula or blastocyst) were used to compare differences among treatments.
Due to a possible direct effect on pregnancy rates, embryo quality and stage were used as
covariates and location was included as a random effect. Differences in individual least
squares means were protected by using Tukey-Kramer method. A P value less or equal to
0.05 was considered statistically significant.
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4. Results
Results from the initial experiment indicated that culture of in vivo-derived bovine
embryos in medium containing AL-8810 improved blastocyst development when
compared to PGF (58% vs. 46%, respectively; P=0.05; Figure 13). In addition, a strong
tendency on improving embryo development was observed in embryos cultured in 1000
AL + PGF-10 compared to those cultured in PGF-10 (57% vs. 46%, respectively;
P=0.07; Figure 13). Blastocyst development of embryos cultured in CON tended to be
lower when compared to embryos in PGF-10 (55% vs. 46%, respectively; P=0.12; Figure
13). Relative abundance of Na+/K+ ATPase α1 (Figure 14) and ZO-1 (Figure 15)
transcripts did not differ between treatments. Moreover, pregnancy rates after transfer of
embryos recovered with medium containing AL-8810 were higher than those obtained
after transfer of embryos recovered with flushing medium without AL-8810 (46% vs.
36%; P=0.04; Figures 16). No differences on pregnancy rates by quality or stage or by
treatment interactions on pregnancy rates were observed (Figures 16 and 17;
respectively).

5. Discussion
Currently, MOET programs in beef and dairy cows are utilized worldwide for
rapid acquisition of superior animals. However, the costs of superovulation treatment,
labor, and the variability in superovulatory response and pregnancy rates after embryo
transfer make this technique economically unappealing to the great majority of producers.
Several factors such as recipient management, age of recipient animal (reviewed by
(Stroud and Hasler, 2006), synchrony between estrous cycles of donor and recipient cows
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Figure 13. In vitro blastocyst development of frozen-thawed in vivo-derived embryos
cultured in KSOM medium with 1000 nM AL-8810 (AL, n= 94), 1000 nM AL-8810 + 10
ng/mL prostaglandin F2α (AL+PGF, n= 94), 10 ng/mL prostaglandin F2α (PGF, n= 94),
and Control (CON, n= 91). Standard errors were ± 3.7.
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Figure 14. Relative abundance of Na+/K+ ATPase mRNA expression of in vivo-derived
embryos cultured in KSOM medium with 1000 nM AL-8810 (AL), 1000 nM AL-8810 +
10 ng/mL prostaglandin F2α (AL+PGF), 10 ng/mL prostaglandin F2α (PGF), and Control
(CON). Standard errors were ± 0.14 for each treatment.
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Figure 15. Relative abundance of ZO-1 mRNA expression of in vivo-derived embryos
cultured in KSOM medium with 1000 nM AL-8810 (AL), 1000 nM AL-8810 + 10
ng/mL prostaglandin F2α (AL+PGF), 10 ng/mL prostaglandin F2α (PGF), and Control
(CON). Standard errors were ± 0.25 for each treatment.
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Figure 16. Pregnancy rates following transfer of embryos collected in medium containing
AL-8810 were increased compared to controls. The interaction of collection medium
treatment with embryo quality 1 or 2 did not differ. a,b Values differ between treatments;
P<0.05. Standard errors were ± 0.06 for AL-8810 and Con flush medium, and ± 0.06,
±0.08, ±0.06, ±0.09 for the interaction of AL-8810 with quality 1, AL-8810 with quality
2, Con with quality 1, and Con with quality 2.
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Figure 17. Pregnancy rates following transfer of embryos collected in medium containing
AL-8810 were increased compared to controls. The interaction of collection medium
treatment with stage of the embryo (compact morula or blastocyst) did not differ. a,b
Values differ between treatments; P<0.05. Standard errors were ± 0.06 for AL-8810 and
Con flush medium, and ± 0.07, ±0.07, ±0.07, ±0.08 for the interaction of AL-8810 with
compact morula, AL-8810 with blastocyst, Con with compact morula, and Con with
blastocyst.
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(Wright, 1981), infectious diseases (Vanroose et al., 2000), toxins (Woclawek-Potocka et
al., 2005), uterine environment composition (elevated concentrations of urea and PGF2α
(Schrick et al., 1993; Butler, 1998; Scenna et al., 2005), and several others factors, can
influence pregnancy rates following embryo transfer to recipient cows. Pregnancy rates
after non-surgical embryo transfer of in vivo-derived frozen-thawed (ethylene glycol)
embryos is about 40 to 55% (Leibo, 1986; Malayer et al., 1990; Nibart and Humblot,
1997; Lester and McNew, 1999), whereas those obtained after transfer of fresh embryos
are about 55% to 80% (Hasler, 2001). Development of new strategies aimed at increasing
pregnancy rates after embryo transfer will increase efficiency of this technique and lower
costs to cattle owners. Therefore, the objective of this study was to reduce reproductive
losses associated with negative effects of PGF2α on the embryo after performing embryo
transfer in cattle.
In the cow, hatching is a critical step for establishment of a successful pregnancy
because it allows filamentous development of the embryo and posterior attachment of the
embryo to the uterine endometrium. Similarly, low implantation rates of in vitrofertilized human embryos are largely due to impaired development and hatching of
blastocyst (Magli et al., 1998). In cattle, accumulation of fluid (between days 8 and 10
after fertilization) within the blastocoel cavity of the blastocyst distends the ZP until it
ruptures allowing hatching of the blastocyst by protrusion through the opening in the ZP
(Flechon and Renard, 1978; Massip and Mulnard, 1980). Accumulation of fluid within
the blastocoel cavity is achieved by a sodium concentration gradient created by the
presence and activity of Na+/K+-ATPase pump (Biggers et al., 1988) at the basolateral
surface of the trophectoderm epithelium. Additionally, presence of a junctional apical
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complex (formed by tight junction and adheren junctions at the apical part of the TE
epithelium) prevents uncontrolled leakage of this fluid from the blastocoel cavity
(Watson et al., 1992; Bavister, 1995).
Manipulation of the reproductive tract has been shown to increase release of
PGF2α from the uterine endometrium in the cow (Scenna et al., 2005), sow (Kunavongkrit
et al., 1984), and mare (Kask and Odensvik, 1995). Elevated uterine concentrations of
PGF2α in the uterine lumen caused by mechanical manipulation of the uterus at the time
of embryo transfer may create a “hostile environment” for embryonic development. In
fact, Schrick et al. (1993) observed that quality of bovine embryos tended to be
negatively correlated with concentrations of PGF2α in the flushing media. Furthermore,
Scenna et al. (2004) demonstrated that development of in vitro-produced pre-compacted
embryos to blastocyst stage and hatching rates of in vivo-derived bovine embryos were
directly reduced by PGF2α. Prostaglandin F2α has also been shown to decrease pregnancy
rates in cows provided supplemental progesterone (Buford et al., 1996; Seals et al., 1998;
Lemaster et al., 1999). Further involvement of PGF2α as an embryotoxic agent was
observed on embryonic development of rat, mouse, and rabbit embryos in vitro (Harper
and Skarnes, 1972; Maurer and Beier, 1976; Breuel et al., 1993).
In our initial study, orthogonal contrast indicated a strong tendency for improved
in vitro development of embryos treated with AL-8810 before exposure to PGF2α (1000
AL + PGF-10 group) when compared to embryos treated with PGF2α alone (PGF-10
group). Moreover, evaluation of relative abundance of important genes participating in
blastocyst formation and successful hatching (Na+/K+ ATPase α1 isoform and ZO-1, a
protein constituent of tight junctions) of bovine embryos did not differ among treatments.
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Therefore, negative effects of PGF2α on embryonic development of in vivo-derived
bovine embryos do not appear to be mediated by a reduction on gene expression of genes
participating in blastocyst formation nor hatching. However, another explanation for the
lack of effects of PGF2α on gene expression in those two genes may be related to the
presence of several other Na+/K+ ATPase isoforms (Betts et al., 1997) and several other
proteins that contribute to tight junction assembly (Stevenson and Keon, 1998).
Prostaglandin F2α may also decrease embryonic development by altering the activity of
the Na+/K+ ATPase pump and increasing permeability of tight junctions through posttranslational modification (especially by activation of PKC) of these proteins.
It worth noting that the percent difference between 1000 AL + PGF-10 (57%) and
PGF-10 (46%) on development to blastocyst in vitro was in the order of 11%. Similarly,
a 10% difference on pregnancy rates after transfer of embryos previously exposed to AL8810 (46%) or embryos not exposed to the receptor antagonist (36%) was observed in
vivo. Since uterine manipulation induces synthesis and release of PGF2α from the uterine
endometrium to the uterine lumen, in vitro development of embryos in 1000 AL + PGF10 and PGF-10 would “mimic” our in vivo conditions when transferring embryos treated
with (Flush-AL) or without AL-8810 (Flush-Con) into recipient cows. Therefore, our in
vitro conditions appear to represent an excellent model for the study of PGF2α effects on
development of bovine embryos as well as for the development of therapeutic strategies
that can later be applied in vivo.
The improvement on pregnancy rates observed in our study agreed with previous
data from our laboratory in which administration of flunixin meglumine to recipient cows
at the time of embryo transfer increased pregnancy rates (Scenna et al., 2005). In
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addition, Elli et al. (2001), McNaughtan et al. (2002), Pugh et al. (2004) and Purcell et al.
(2004) also reported beneficial effects of prostaglandin synthesis inhibitors on pregnancy
rates after embryo transfer in recipient cows. The increase on pregnancy rates in the
present study after utilization of a selective FPr antagonist (10%) was higher than the
increase on pregnancy rates observed after administration of flunixin meglumine (5%)
reported by Scenna et al. (2005). An explanation for differences on pregnancy rates
between these two studies may be explained by 1) a more efficient means of inhibiting
PGF2α effects inside the uterus (readily available FPr antagonist in the collection medium
vs. parenteral administration of flunixin meglumine), and/or 2) by only inhibiting the
effects of PGF2α on the embryo by AL-8810 vs. the inhibition of all prostaglandins
synthesis with the administration of flunixin meglumine, a non-specific inhibitor of
cyclooxygenase synthases-1 and -2 enzymes (Cheng et al., 1998; Campbell and
Blikslager, 2000). As a consequence, flunixin meglumine inhibits synthesis of all
prostaglandins, including those considered beneficial for embryo development (especially
PGE2; (Biggers et al., 1978; Gurevich et al., 1993).
Our results suggest that inability of PGF2α to interact with its receptors (by the
utilization of a PGF2α receptor antagonist in the flushing medium) on bovine embryos at
the time of embryo recovery improves pregnancy rates of those embryos transferred to
recipient cows. These findings will increase the efficiency of embryo transfer programs
in cattle and lower the costs associated with this procedure by increasing the number of
pregnancies after transfer.
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CHAPTER 6
SUMMARY

Reproductive losses associated with the beef industry in the United States are
estimated to cost $500 million dollars annually (Bellows et al., 2002). Previous studies
have shown detrimental effects of prostaglandin F2α (PGF2α) on in vitro development of
rat, rabbit and bovine embryos (Maurer and Beier, 1976; Breuel et al., 1993; Scenna et
al., 2004). Moreover, elevated concentrations of PGF2α decreased embryonic
development, quality and hatching ability of embryos and pregnancy rate in cows, even
in the presence of supplemental progesterone (Schrick et al., 1993; Buford et al., 1996;
Lemaster et al., 1999; Elli et al., 2001; Hockett et al., 2004; Sales et al., 2004). Therefore,
PGF2α is a major cause of reproductive inefficiency in cows and results in vast economic
losses for the cattle industry.
To date, the mechanisms through which PGF2α reduces embryonic survival and
development in the cow are still unclear. In addition, the presence of prostaglandin PGF2α
receptors (FPr) in early stage bovine embryos has not been documented in the literature.
Lack of information regarding presence of FPr in bovine embryos did not allow for direct
therapeutic strategies aimed at inhibiting PGF2α effects associated with reproductive
inefficiency in cattle. However, non-selective inhibitors of prostaglandin synthesis have
been shown to increase pregnancy rates after embryo transfer to recipient animals in
cattle (Elli et al., 2001; McNaughtan et al., 2002; Pugh et al., 2004; Purcell et al., 2004;
Scenna et al., 2005).
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For the first time in the literature, we demonstrated the presence of FPr mRNA
and protein in pre-attachment bovine embryos. Discovery of FPr in bovine embryos
allowed us to develop new therapeutic strategies to improve embryo quality, development
and survival in cows. Our initial experiments determined that the FPr antagonist AL-8810
had no negative (or toxic) effects on development of in vitro- and in vivo-derived bovine
embryos. Secondly, we observed that AL-8810 inhibited detrimental effects of PGF2α
development of in vitro- and in vivo-derived bovine embryos. Finally, we demonstrated
that addition of AL-8810 to the collection medium during recovery of bovine embryos in
donor cows was able to increase pregnancy rates following transfer of these embryos to
recipient cows. Thus, our results indicated that addition of AL-8810 inhibits direct
negative effects of PGF2α on in vitro (before compaction) and in vivo (after compaction)
embryo development by preventing PGF2α to interact with its cell surface receptor in
bovine embryos.
During embryo transfer, manipulation of the reproductive tract may trigger an
inflammatory process in the uterus with release of several chemical mediators. One of
these mediators, TNF-α, has been shown to activate cPLA2 in endometrial cells (Okuda et
al., 2002). Activation of cPLA2 in endometrial cells will stimulate PGF2α synthesis and
release into the uterine lumen. In fact, Scenna et al. (2005) reported increased plasma
concentrations of PGF2α following manipulation of the reproductive tract after embryo
transfer. Prostaglandin F2α released into the uterine lumen may also stimulate its own
synthesis and release from endometrial cells (Wade and Lewis, 1996), and thus,
increasing intralumenal concentrations of PGF2α. Based on our results, we hypothesize
that PGF2α alters embryonic development by binding to its own receptor and triggering a
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cascade of events (Figure 18) leading to: 1) inability to compact of pre-compacted
embryos, and 2) decrease hatching rates of compacted embryos. It can be speculated that
the effects of PGF2α are not all or none, but enough to cause a temporary decrease on
embryonic development. These effects will result in reduced embryo development and
hatching rates. As a consequence, an asynchrony between the uterus and the stage of the
embryo will result in a retarded embryo not able to secrete interferon-τ at the moment of
spontaneous luteolysis in the cow and resulting in embryonic loss.
We hypothesize that binding of PGF2α to its receptor causes downstream signaling
events (mobilization of intracellular Ca++, activation of PKC and MAPK’s) leading to
disruption, destruction or synthesis inhibition (by decreasing gene expression) of cell-cell
adhesion molecules, but especially E-cadherin and tight junctions. In addition, PGF2α–
associated signaling events may cause post-translational regulations of several important
proteins, such as Na+/K+ ATPase pump, and decrease their physiological activities (Kim
and Yeoun, 1983). Therefore, effects of PGF2α will result in a decrease on the ability of
the embryo to either compact (especially by altering E-cadherin assembly or activity) or
hatch from the zona pellucida (especially by altering tight junctions and Na+/K+ ATPase
pump assembly or activity) (Figure 18).
Improving pregnancy rate after embryo transfer in cows using AL-8810 will
allow for development of new therapeutic techniques in other species, including humans,
to increase reproduction and success rates. These findings will also allow to increase the
efficiency of embryo transfer programs in cattle and to lower the costs associated with
this technique, making it more appealing to cattle owners. Lastly, inhibition of
detrimental effects of PGF2α on bovine reproduction will result in better reproductive
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Figure 18. Proposed mechanisms of action of PGF2α on development of bovine embryos.
Following synthesis and release of PGF2α to the uterine lumen, PGF2α can interact with its
own receptor (FPr) at the cell membrane of blastomeres and trigger a cascade of signaling
events (G-protein/Phospholipase C/Ca++/DAG/PKC/MAPK) or diffuse to the cytoplasm
of the blastomeres without interacting with its receptor. In addition, PGF2α can stimulate
its own production in the uterine endometrium increasing its concentrations in the uterine
lumen and also inducing synthesis of matrix metalloproteinases with the ability to
destruct tight junctions. These signaling events will modify assembly and/or functions of
E-cadherin, tight junctions or Na+/K+ ATPase proteins affecting compaction and hatching
of the embryos.
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efficiency (higher pregnancy rates) and higher monetary earnings to the cattle industry
(increase on cattle sales).
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